Document:

License and Distribution Agreement

 Exhibit 10.4 
 CONFIDENTIAL 
 GALECTIN-3 LICENSE AND
DISTRIBUTION AGREEMENT 
 This GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT (this “Agreement”),
entered into as of November 11, 2009 (the “Effective Date”), by and between Abbott Laboratories, a corporation of the state of Illinois, having its principal place of business at 100 Abbott Park Road, Abbott Park, IL 60064-3500
(“Abbott”) and BG Medicine, Inc., a corporation of the state of Delaware, having its principal place of business at 610 Lincoln Street North Waltham, MA 02451 (“BGM”). 
 W I T N E S S E T H: 
 WHEREAS, Abbott and BGM are parties with Fujirebio Diagnostics, Inc. (“FDI”) to that certain Umbrella Product Development Agreement dated as of November 11, 2009 (the
“Umbrella Agreement”), under which BGM funds the development of selected Products which shall be used on Abbott’s Architect® line of instruments; 
 WHEREAS, Abbott desires to promote and market Products in the Territory (as hereinafter defined); 
 WHEREAS, BGM owns or otherwise controls or has rights to certain intellectual property rights which may cover Products (“Patent Rights” as hereinafter defined); 
 WHEREAS, BGM desires to grant to Abbott under Patent Rights a license to make, have made, use, offer for sale, sell, have
sold, import, distribute and have distributed Products in the Territory; and 
 WHEREAS, Abbott desires to obtain
such license. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreement contained
herein, and upon the terms and subject to the conditions set forth below, Abbott and BGM hereby agree as follows: 
 ARTICLE 1. DEFINITIONS 
  

	1.1	“Affiliate” means, with respect to any Party (as hereinafter defined), any entity which controls, is controlled by or is under common control with,
such Party. As used herein, the term “control” means with respect of any entity, the power to direct or cause the direction of the management and policies of that entity, whether directly or indirectly and whether through ownership of more
than fifty percent (50%) of the outstanding voting stock or equity of an entity, by contract or otherwise. 

  

	1.2	“AUP” shall be the total sales of Tests divided by the number of Tests sold to Third Parties (as hereinafter defined) by BGM, Abbott and/or the Other
Licensees, as the context may require. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	1.3	“Calendar Quarter” means a period of three (3) consecutive calendar months of a calendar year, beginning on
January 1, April 1, July 1 or October 1. 

  

	1.4	“Change of Control” means: (a) the consolidation or merger of BGM with or into any Third Party wherein the shareholders of BGM immediately prior
to such transaction shall cease to be the holders of at least fifty percent (50%) of the outstanding securities of the surviving corporation in such transaction; (b) the assignment, sale, transfer, lease or other disposition of all or
substantially all of the assets of BGM relating to the business to which this Agreement relates; or (c) the acquisition by any Third Party or group of Third Parties acting in concert, of beneficial ownership (within the meaning of Rule 13d-3 of
the Securities and Exchange Commission (“SEC”) under the Securities and Exchange Act of 1934) of more than fifty percent (50%) of the outstanding shares of voting stock of BGM. 

  

	1.5	“Commercially Reasonable Efforts” shall mean those efforts in accordance with the subject Party’s efforts and resources normally used by it for a
product owned by it, or to which it has rights, which is of similar market potential at a similar stage in its product life, taking into account the competitiveness of the marketplace, the proprietary position of the product, the regulatory
structure involved, the profitability of the applicable product, and other relevant factors including technical, legal, scientific or medical factors. 

  

	1.6	“Confidential Information” means any proprietary, confidential, non-public information, data, samples, plans, marketing plans, reports, forecasts,
formulae, processes, technical or commercial information, trade secrets, patent applications, improvements, invention disclosures or know-how disclosed in writing by one Party to another Party under this Agreement, as well as information disclosed
in any other form and identified as “Confidential Information” at the time of disclosure, to the extent such disclosure is reduced to writing, marked “Confidential” and provided to the receiving Party within thirty (30) days
after oral disclosure. 

  

	1.7	“First Commercial Sale” means the date on which Abbott (or its Affiliate or agent) first sells a Product to a Third Party in the Territory for monetary
consideration. 

  

	1.8	“Galectin-3” means the soluble galactoside-binding protein coded by the LGALS3 gene. 

  

	1.9	Reserved. 

  

	1.10	“Knowledge” means, with respect to BGM, the actual knowledge, after due inquiry, of the chief executive officer or any executive officer (as defined
for purposes of Section 14 of the Securities Exchange Act of 1934, as amended) of BGM. 

  

	1.11	“Party” means Abbott or BGM and “Parties” means Abbott and BGM. 

  

	1.12	 “Patent Rights” means the patents and patent applications listed on Exhibit 1.12 and: (a) all patents and patent
applications owned or controlled by BGM during the Term of the Agreement relating to Galectin-3 or Products; (b) the patents or patent applications

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 2 

 
acquired by BGM during the Term of this Agreement relating to Galectin-3 or Products; (c) all patents or patent applications covering Galectin-3 or Products under which BGM becomes licensed
and has the right to sublicense; (d) all patents arising from applications identified in (a), (b) or (c); (e) any extension, renewal or reissue of a patent identified in (a), (b), (c) or (d); (f) any and all foreign
counterparts or equivalents issued of any patents identified in (a) through (d); and (g) any reexamination or renewal of a patent identified in (a), (b), (c) or (d). 
  

	1.13	“Product(s)” means individually and collectively Galectin-3 assay kits, Galectin-3 control kits and Galectin-3 calibrator. 

  

	1.14	“Steering Committee” means a committee of individuals from the Parties which shall meet on a regular basis as the Parties require, which shall be
composed of equal numbers of individuals from each Party. The Steering Committee shall review Product development, Galectin-3 marker development, clinical studies and any other relevant issue regarding the Product that comes up during the Term.

  

	1.15	“Term” as the meaning set forth in Section 11.1. 

  

	1.16	“Territory” means every country in the world. 

  

	1.17	“Test” means an individual Galectin-3 assay test for a single determination of Galectin-3; provided that a Test does not include tests included in
Galectin-3 control kits or Galectin-3 calibrator kits. 

  

	1.18	“Third Party” means a person or entity other than Abbott, BGM or any of each Party’s Affiliates. 

  

	1.19	“Valid Claim” means any claim of an issued and unexpired patent within Patent Rights that is applicable with respect to a Product, which claim has not
been held invalid or unenforceable by a decision of a court or governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal or which has not been admitted by the patentee to be invalid or unenforceable
through reissue, disclaimer or otherwise. In the event a patent has been held to be invalid or unenforceable, and an appeal is pending, such claims shall not be considered a Valid Claim until reinstated by a final decision, not subject to further
appeal, of a court or governmental agency of competent jurisdiction; provided, however, that once reinstated, a Valid Claim shall be considered a Valid Claim retroactively as if the patent had never been held to be invalid or
unenforceable. 

 ARTICLE 2. GRANT OF LICENSES 
  

	2.1	 License Grant. BGM hereby grants to Abbott and its Affiliates a royalty-bearing license under Patent Rights to make, have made, use, offer for
sale, sell, have sold, import, distribute and have distributed Products in the Territory. Abbott shall not have the right to grant a sublicense to any Third Party. Notwithstanding the foregoing license grant,

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 3 

 
prior to selling, having sold, importing, distributing, having distributed or otherwise commercializing a Product for use on a point-of-care platform, Abbott will first notify BGM in writing of
its desire to do so, and the Parties will negotiate in good faith to amend this Agreement to provide for Product Fees for point-of-care Tests and other terms related to point-of-care Tests that may be agreed upon by the Parties. 
  

	2.2	Additional Licensees; Most Favored Terms. BGM shall have the right to license Patent Rights to no more than four (4) Third Parties (“Other
Licensees,” and together with Abbott, the “BGM Licensees”) for such Other Licensees to make, have made, use, offer for sale, sell, have sold, import, distribute, have distributed a Galectin-3 assay, whether on an automated
system or not; provided, that such Other Licensees’ Galectin-3 assays may be commercialized only under the Other Licensees’ names and brands and only with respect to platforms or technology that are owned or controlled by such Other
Licensees, unless Abbott otherwise consents after considering in good faith an alternative proposal by BGM; provided, further, that (a) beginning five (5) years after the date of First Commercial Sale, BGM may license Patent
Rights to additional Third Parties (who shall then be considered Other Licensees) to offer for sale, sell, have sold, import, distribute or have distributed a Galectin-3 assay; and (b) no Other Licensee shall receive more favorable financial
terms than those set forth in this Agreement for Abbott. If BGM enters into an arrangement with any Other Licensee for a Galectin-3 assay that would reasonably be believed to contain more favorable financial terms than those set forth in this
Agreement, BGM shall so inform Abbott within ten (10) days of entering such arrangement, and Abbott shall be entitled to the benefit of the more favorable financial terms of such other arrangement from the date of the arrangement with the Other
Licensee. In the event Abbott deems such Other Licensee’s financial terms to be more favorable and desires to license Patent Rights under such alternative financial terms, Abbott will notify BGM within ten (10) days of learning of these
terms, after which the Parties will develop and execute the necessary amendments to incorporate the more favorable financial terms into this Agreement. Other Licensees shall not have the right to grant sublicenses to any Third Party. For avoidance
of doubt, BGM and the BGM Licensees shall be free to enter into agreements for development, manufacturing or distribution of their products, and such agreements shall not be considered licenses to Patent Rights for purposes of this Section 2.2.

  

	2.3	Updates to Patent Rights. BGM shall be responsible for updating Exhibit 1.12 to include all developments and updates to all patents listed therein and
providing written notice to Abbott. Abbott shall have no payment obligations pursuant to Section 3.1 with respect to new Patent Rights unless and until BGM notifies Abbott, in writing, that new patents have issued and are included within the
Patent Rights. 

 ARTICLE 3. FEES AND PAYMENTS 
  

	3.1	 Product Fee. Abbott shall pay to BGM a fee (the “Product Fee”) consisting of a product access fee of [***] (US $[***]) and a
marketing service fee of [***] ($[***]) for each

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 4 

 
Test sold by Abbott (or its Affiliate or agent) to a Third Party in the Territory, subject to the following: 
  

	 	(a)	 Specifically for the Products manufactured by FDI under the Umbrella Agreement for use on Abbott’s Architect® line of instruments, Abbott shall pay the Product Fee only if (i) BGM obtains a Valid Claim in the country(ies)
where the Architect-specific Products are sold within three (3) years from the First Commercial Sale; and (ii) there are no unlicensed competitors selling Galectin-3 products that could compete with the Architect-specific Products in such
country(ies). If BGM does not secure a Valid Claim in such country (ies) within three (3) years after First Commercial Sale, or if there are unlicensed competitors in such country (ies), the Parties shall meet to renegotiate the Product Fee
payable with respect to the Architect-specific Products. 

  

	 	(b)	For all other Products, Abbott shall pay the Product Fee for sales of Product in countries where, but for the license granted in this Agreement, Abbott’s sales of
such Products would infringe BGM’s Valid Claims. 

  

	3.2	Product Fee Reductions. If any of the following events occur during the Term, Abbott shall be entitled to a reduction in the Product Fee paid per Test by Abbott
to BGM: 

  

	 	(a)	BGM does [***] for the [***] an [***] of at least [***] (US $[***]), as demonstrated by [***] or other [***]; 

  

	 	(b)	A [***] is [***], and the [***] amount for the Test either is [***] to or [***] for a [***] test; 

  

	 	(c)	[***] or other [***] an [***] of at least [***] (US $[***]) per Test, as demonstrated by [***] or other [***]; 

  

	 	(d)	In the event either Party [***] the [***] of [***] in the [***] by BGM and the BGM Licensees in any [***] period following the first commercial launch of a Galectin-3
assay by [***] is [***] (US $[***]) per Test, then it shall notify the other Party and the Parties shall promptly [***] to [***]. If the [***] whether the [***] by BGM and the BGM Licensees in such [***] period is [***] (US $[***]), they will agree
upon an [***] to [***] a [***] and report the [***] to both Parties. If the report determines that the [***] of [***] by BGM and the BGM Licensees in such [***] period was [***] (US $[***]) per Test, then the provisions of [***], and BGM shall [***]
the [***]. If the report determines that the [***] of [***] by BGM and the BGM Licensees in such [***] period was [***] (US $[***]), then the provisions of [***] and Abbott shall [***] the [***]; 

  

	 	(e)	[***] Galectin-3 product has [***] over a [***] period that is [***] (US $[***]) per Test; 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 5 

	 	(f)	[***] having [***] of [***] per Test for a [***] period [***] (US $[***]) per Test; or 

  

	 	(g)	[***], as contemplated in Section [***], [***] (US $[***]) per Product [***]. 

 If: (1) pursuant to [***] above, an [***] confirms that the [***] by BGM and the BGM Licensees in the given [***] period was [***] (US
$[***]); and (2) the [***] for [***] is [***] (i.e., [***]% or more) than the [***] for [***] by BGM and the BGM Licensees that are [***] to the Products (e.g., [***]); then [***] to a [***] in [***]. 
 If the Parties are unable to agree on the amount of the reduction of the Product Fee, the matter shall be resolved by the Alternative
Dispute Resolution process set forth in Section 12.12 and Exhibit 12.12. If at any time the [***] or its Affiliates falls [***] (US $[***]) per Test, [***], in its sole discretion, shall have the right to [***] the [***], and upon
such [***], [***] and [***] to [***], [***] or [***]. 
  

	3.3	Test Rebate. As consideration for [***] the [***] of the [***] and [***] is [***], Abbott shall receive a product access fee rebate of [***] (US $[***]) for
every Test sold by Abbott, Abbott shall have the right to deduct the rebate from the quarterly payment otherwise due and payable to BGM. 

  

	3.4	Royalty Payable Only Once. The license fee set forth in Section 3.1 shall be payable hereunder only once with respect to a Test, regardless of the number of
patents set forth in Patent Rights that cover Products. 

  

	3.5	Reductions to Fees Due to Third Party Licenses. Abbott, in its sole discretion, may determine that additional royalty-bearing licenses are required from Third
Parties in order to make, have made, use, offer for sale, sell, have sold, import, distribute, have distributed Products in the Territory. If Abbott so determines that such licenses are required specifically to make, have made, use, offer for sale,
sell, have sold, import, distribute, or have distributed Galectin-3 assays for indications of the Product in the Territory, Abbott shall notify BGM within ten (10) days of making such determination. After notification BGM will attempt to
resolve the matter in a timely manner and to Abbott’s satisfaction. However, if Abbott, at any time, in its sole discretion, determines that such license is required Abbott will negotiate in good faith with the Third Party and if Abbott after
such negotiations obtains the additional royalty-bearing licenses, Abbott has the right to deduct the royalties actually paid to such Third Parties from the fees payable to BGM; provided, that such deduction shall not be for more than [***] percent
([***]%) of the amounts otherwise due and payable to BGM hereunder. 

  

	3.6	Payments. All payments shall be made quarterly. Abbott shall pay BGM within sixty (60) days of the end of each Calendar Quarter during which sales occurred.

  

	3.7	Product Fee Reports. With each payment hereunder, Abbott shall deliver to BGM a report describing on either a country-by-country or territory-by-territory basis
the number of Tests sold by Abbott and its Affiliates. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 6 

	3.8	Currency Conversion. All payments made hereunder shall be in US Dollars. AUP shall be calculated and reported in US Dollars. For purposes of calculating AUP,
sales made in a currency other than US Dollars shall be converted using Abbott’s standard conversion methodology, which is consistent with generally accepted accounting principles. The standard conversion methodology for sales is based on the
monthly average (the spot rate for the end of the month immediately prior to that in which AUP is being calculated plus the spot rate for the end of the month for which AUP is being calculated, divided by two). 

  

	3.9	Transfer of Payments. All payments due and payable hereunder to BGM shall be made by wire transfer to the following bank account number of such bank or other
location as may be designated in writing by BGM from time to time: 

 Wire Transfer Information: 
 Bank Name: [***] 
 Bank Address: [***] 
 Account Number: [***] 
 Swift Code: [***] 
  

	3.10	Tax Withholding. Insofar as any fees that are due to BGM under this Agreement with respect to sales of Products outside the United States are subject to taxation
where the taxes are imposed on BGM, BGM shall bear all such taxes. BGM hereby authorizes Abbott to withhold such taxes from the payments that are payable to BGM hereunder if Abbott is either: (a) required to do so under the tax laws of the
country of sale; or (b) directed to do so by an agency of such government. Abbott shall provide BGM with the best available evidence of payment whenever Abbott deducts such taxes from any payment due BGM. Where any sum due to be paid to BGM is
subject to any withholding or similar tax, the Parties shall use Commercially Reasonable Efforts to do all such acts and things and to sign all such documents as will enable them to take advantage of any applicable double taxation or tax reduction
agreement or treaty. If there is no applicable double taxation or tax reduction agreement or treaty, or if an applicable double taxation or tax reduction agreement or treaty reduced but does not eliminate such withholding or similar tax, Abbott or
its Affiliates shall pay such withholding or similar tax to the appropriate government authority, deduct the amount so paid from the amount otherwise due and payable to BGM, and secure and send to BGM the available evidence of such payment.

  

	3.11	Record Keeping; Audits. 

 (a) Abbott shall keep full and accurate accounting records of all Tests and Excluded Tests (as defined in Section 6.4) sold in sufficient detail to determine the Product Fees payable by Abbott to
BGM. Upon reasonable written notice to Abbott, BGM shall have the right, during normal business hours, to have an independent certified public accountant, selected by BGM and acceptable to Abbott, audit Abbott’s records pertaining to the number
of Tests and Excluded Tests sold on a confidential basis to

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 7 

 
verify the Product Fees payable pursuant to this Agreement; provided, however, that such audit shall not: (a) take place more frequently than once per calendar year; and
(b) cover records for more than the preceding three (3) years. Such certified public accountant shall enter into a non-disclosure agreement with confidentiality provisions at least as stringent as those set forth in this Agreement, and
shall only disclose the conclusion of such audit to BGM and Abbott, and not any of Abbott’s customers, pricing or other Confidential Information. The results of such audit shall be binding on both parties. Any adjustment in payment shall be
made upon demonstration of any underpayment. 
 (b) BGM shall keep (i) full and accurate accounting records
of its own AUP, in sufficient detail to determine if any of the circumstances set forth in Section 3.2 have occurred. Upon reasonable written notice to BGM, Abbott shall have the right, during normal business hours, to have an
independent certified public accountant, selected by Abbott and acceptable to BGM, audit BGM’s records pertaining to the sales of Galectin-3 products on a confidential basis to verify the AUPs of such products for the purposes of this
Agreement; provided, however, that such audit shall not: (a) take place more frequently than once per calendar year; and (b) cover records for more than the preceding two (2) years. Such certified public accountant shall
enter into a non-disclosure agreement with confidentiality provisions at least as stringent as those set forth in this Agreement, and shall only disclose the conclusion of such audit to BGM and Abbott, and not any of BGM’s customers, pricing or
other Confidential Information. The results of such audit shall be binding on both parties. 
  

	3.12	Cost of Audits. All fees and expenses of any audit requested by BGM pursuant to Subsection 3.11 shall be borne by BGM; provided, however,
that if any audit reveals that Abbott underpaid Product Fees due to BGM under this Agreement as to the time period being audited by more than [***] percent ([***]%) of the amount that was payable for such time period, and as long as the underpayment
amount is at least [***] ($[***]), Abbott, in addition to paying BGM any underpayment, shall reimburse BGM for the cost of such audit. 

 ARTICLE 4. GALECTIN-3 PROMOTIONAL ACTIVITIES 
  

	4.1	Abbott’s Sales Efforts. During the Term of this Agreement, Abbott shall use Commercially Reasonable Efforts to promote, market, sell and distribute Products
throughout the Territory. Such efforts may include preparing collateral marketing materials, conducting advertising, presenting educational seminars, detailing, displaying exhibits at trade shows and ensuring representation and attendance at
industry meetings, all of which shall be performed in accordance with Abbott’s usual and customary practices that Abbott would use for Abbott’s products of a similar nature. Abbott solely shall be responsible for the costs incurred in such
efforts hereunder. As part of its promotion and marketing efforts, Abbott may elect to offer Products to potential customers at no charge for evaluation purposes, which Products shall not be subject to Section 3.1 or reported pursuant to
Section 3.7. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 8 

	4.2	Selling Price. Abbott, in its sole discretion, shall determine the final sales price of Products sold by Abbott to Third Parties in the Territory, and no other
term or provision of this Agreement shall be interpreted or deemed to provide BGM with any right to determine or influence the final sales price of Products sold by Abbott hereunder. 

  

	4.3	Development of Promotional and Marketing Materials for Products. Promptly following the Effective Date, BGM shall deliver to Abbott copies of any promotional
marketing materials owned or controlled by BGM that may be used by Abbott in the promotion and sale of Products. BGM represents and warrants that the statements made in any promotional marketing materials owned or controlled by BGM and provided to
Abbott shall be accurate and complete in all material respects. Abbott also shall have the right to develop and prepare, at Abbott’s sole discretion and at its own cost, promotional and marketing materials for use in its sale and distribution
of Products. Abbott shall be responsible for the accuracy of all statements made in all materials developed by Abbott. 

  

	4.4	Promotional Activities of BGM. BGM or its designee, at its sole cost, shall promote the utility of the marker Galectin-3 in the Territory. As part of its
responsibilities hereunder, BGM shall use Commercially Reasonable Efforts to accomplish the activities described in Exhibit 4.4, or as adjusted by mutual written agreement of the Parties at the quarterly Steering Committee meetings. BGM shall
not promote any BGM Licensee’s Galectin-3 products over any other BGM Licensee’s Galectin-3 products. 

  

	4.5	Exclusivity. During the Term, Abbott shall not develop, manufacture or commercialize a Galectin-3 assay other than Product if such other assay would fall within
the claims identified in the patents included in the Patent Rights and for so long as BGM holds all Patent Rights and intellectual property necessary to sell Products subject to these claims. 

 ARTICLE 5. CLINICAL STUDIES AND CLINICAL INDICATIONS 
  

	5.1	Clinical Studies and Clinical Indications. BGM shall use Commercially Reasonable Efforts to validate the clinical use of Galectin-3 as described on Exhibit
5.1 and any amendments added to Exhibit 5.1 by mutual written agreement of the Parties. The Parties shall discuss the protocols, intended use objectives, status, results and opportunities for expanded clinical claims for the Products
during the quarterly Steering Committee meetings. 

 ARTICLE 6. INTELLECTUAL PROPERTY 
  

	6.1	 Inventions Covering Product. BGM shall own all right, title and interest in and to all inventions during the Term specifically covering the rare
reagents used in the Product made pursuant to the Umbrella Agreement (“Product Inventions”) and inventions covering indications for the use of Galectin-3 (“Indication Inventions”), but only so long as BGM solely
developed or acquired such reagents or solely designed, performed or funded such studies, to identify, patent and protect such new indications for use of Galectin-3 other than any trademark or pre-existing technology or intellectual property of

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 9 

 
Abbott used on, with, for or by the Product, which shall remain the sole property of Abbott. If Product Inventions or Indication Inventions are conceived and reduced to practice hereunder jointly
by Abbott and BGM (“Joint Inventions”) US inventorship laws shall govern the ownership of such Joint Inventions. All Product Inventions and Indication Inventions hereunder owned or controlled by BGM during the Term shall become part
of Patent Rights hereunder. 
  

	6.2	Abbott’s Galectin-3 Intellectual Property. If Abbott solely conceives and reduces to practice any new Product Inventions or Indication Inventions that
result in new patents being sought to cover such new reagents or indications, Abbott shall own such Product Inventions and Indication Inventions, and shall make such Product Inventions and Indication Inventions available to BGM and the Other
Licensees on a non-exclusive, royalty-free basis during the Term, so long as Abbott is compensated for the use of such Product Inventions and Indication Inventions through a negotiated reduction in fees otherwise payable to BGM hereunder by Abbott.
Abbott, in its sole discretion and for its own benefit, shall have the right to exploit such Abbott-owned Product Inventions and Indication Inventions in the Territory. 

  

	6.3	BGM Licensee Galectin-3 Intellectual Property. BGM shall contractually require of each Other Licensee that if an Other Licensee conceives, reduces to practice,
owns controls (through sublicensing or otherwise) any new Product Inventions or Indication Inventions pertaining to Products that are patented or that result in new patents being sought, then Abbott shall be granted a non-exclusive, royalty-free
license, during the Term, to make, have made, use, offer for sale, sell, have sold, import, distribute and have distributed Products using such new Product Inventions or Indication Inventions. 

  

	6.4	Non-BGM Licensee Galectin-3 Intellectual Property. If a Third Party other than an Other Licensee has intellectual property rights for an indication outside of
the Patent Rights, Abbott shall have the right to license such Third Party indication for itself. If Abbott reasonably determines that the use of Product for such indication is not covered by Patent Rights and Abbott receives US FDA clearance or
approval in other territories to sell Product for such indication, Abbott will use Commercially Reasonable Efforts to determine the number of Tests sold for such indication (“Excluded Tests”) in each Calendar Quarter and Abbott may
deduct the number of Excluded Tests from the total Tests sold in a given Calendar Quarter for calculation of the quarterly fee payment to BGM. 

  

	6.5	Patent Prosecution. Each Party shall be solely responsible for the filing and prosecution of patent applications claiming inventions owned by such Party unless
otherwise determined for Joint Inventions. 

 ARTICLE 7. INFRINGEMENT AND ENFORCEMENT 
  

	7.1	Patent Enforcement. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 10 

	 	7.1.1	Notice and Investigation of Infringement. Each Party shall promptly notify the other Party of any possible infringement of BGM’s patents included in Patent
Rights by a Third Party of which such Party has knowledge. BGM shall promptly investigate such possible Third Party infringement and shall inform Abbott of its findings with respect thereto within thirty (30) days, or such longer period as is
required to determine if infringement is occurring, of such notice. 

  

	 	7.1.2	BGM Actions and Participation. During the Term, BGM shall have the first right, but not the obligation, to enforce any and all claims of infringement of any BGM
patents included in Patent Rights, or any related proprietary rights, in its own name, at its own expense and for its own benefit, and Abbott shall take reasonable actions to enable BGM to enforce such action in BGM’s own name, including, but
not limited to, the execution of any necessary papers. Abbott shall join BGM as a party to such prosecution if it is reasonably determined by BGM that Abbott is a necessary party to such prosecution, whereupon BGM shall bear all costs and control
such litigation as if such action had been brought solely in BGM’s name. BGM shall have the right to control all aspects of the enforcement of any claim against a Third Party brought pursuant to the provisions of this Subsection 7.1.2,
including, but not limited to, the right to: (a) select counsel; (b) establish litigation strategies; and (c) pursue settlement discussions and enter into settlements. 

  

	 	7.1.3	Abbott Action. In the event BGM does not pursue enforcement of BGM’s patents as set forth in Subsection 7.1.2, and Abbott reasonably believes that
such infringement shall materially impact Abbott’s ability to market the Products, Abbott shall have the right, but not the obligation, to enforce any and all claims of infringement of any BGM’s patents against such infringement, in its
own name, at its own expense and for its own benefit, and BGM agrees to take all actions reasonably necessary to enable Abbott to enforce such action in its own name, including, but not limited to, the execution of any necessary papers. BGM shall
join Abbott as a party to such prosecution if it is reasonably determined that BGM is a necessary party to such prosecution, whereupon Abbott shall bear all costs and control such litigation as if such action had been brought solely in Abbott’s
name. Abbott shall have the right to control all aspects of the litigation of any claim against a Third Party brought pursuant to the provisions of this Subsection 7.1.3, including, but not limited to, the right to: (a) select counsel,
such selection to be subject to BGM’s written approval, such approval not to be unreasonably withheld; (b) establish litigation strategies, subject to an obligation to confer with BGM regarding such strategies and to give reasonable
consideration to BGM’s input with respect to such strategies; and (c) pursue settlement discussions and enter into settlements. Notwithstanding the foregoing, Abbott shall not settle any such litigation or claim without the prior written
consent of BGM, which consent shall not be withheld unreasonably. 

  

	 	7.1.4	 Proceeds Recovered. Any amount received by Abbott as a result of any proceeding referred to in Subsection 7.1.3, shall be distributed and
paid as

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 11 

	 	 
follows: (a) first, to reimburse Abbott for all expenses incurred by it in connection with such proceeding; (b) second, to reimburse BGM for any Abbott pre-approved expenses incurred by
it in connection with such proceeding; and (c) third, any additional amounts remaining after such application shall be shared equally by the Parties. 

  

	 	7.1.5	Cooperation. The Party controlling the action shall keep the other Party reasonably informed of the progress of the suit, claim or proceeding.

  

	7.2	Defense of Assertions of Infringement of Third Party Patents. 

  

	 	7.2.1	Assertion Against Abbott. In the event of a Third Party assertion against Abbott of patent infringement (or any other violation of a proprietary right of a Third
Party) related to the manufacture, use or sale of the Product(s) in the Territory, Abbott shall vigorously defend such assertion, at its sole expense. Abbott shall promptly notify BGM in writing of the assertion or claim, including details and known
facts regarding such assertion or claim. BGM shall provide, upon Abbott’s request and at Abbott’s sole expense, reasonable assistance for such defense. Abbott shall have the right to settle such assertion on terms acceptable to Abbott;
provided, however, that Abbott shall not enter into any settlement that would affect BGM’s Patent Rights relating to Products without the prior, written consent of BGM. 

 ARTICLE 8. REPRESENTATIONS AND WARRANTIES 
  

	8.1	General Representations and Warranties. Each Party represents and warrants to the other Party as of the Execution Date of this Agreement:

  

	 	(a)	It is a corporation duly organized and validly existing under the laws of its state of incorporation; 

  

	 	(b)	It has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; 

  

	 	(c)	At no time prior to the termination or expiration of this Agreement, shall BGM enter into any transaction which would prohibit or materially impair BGM from fulfilling
its obligations under this Agreement. 

  

	8.2	Patent Representations and Warranties. BGM represents and warrants to Abbott the following as of the Execution Date of this Agreement: 

 

	 	(a)	It is the sole owner of all right, title and interest in and to the patents included in Patent Rights, and no approvals or other documentation are necessary to be
obtained from any Third Party in order for the licenses and rights to be conferred to Abbott hereunder; 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 12 

	 	(b)	There have been no written claims or assertions, or to BGM’s Knowledge any oral claims or assertions, that the making, using, offering for sale, use, or importing
of one or more of the Products infringes the patents or other proprietary right of any Third Party; 

  

	 	(c)	BGM has no Knowledge of any Third Party patents, trademarks or other proprietary rights which are valid and which would be infringed by making, having made, using,
selling, offering for sale or importing Products in the Territory in accordance with the terms of this Agreement; and 

  

	 	(d)	To its Knowledge, BGM is not, and as a result of the execution and delivery of this Agreement, will not be, in violation of, or lose of any rights pursuant to, any
license, sublicense or agreement previously provided to BGM by a Third Party with respect to Patent Rights relating to Products. 

  

	8.3	Abbott Representations and Warranties. Abbott represents and warrants to BGM the following as of the Execution Date of this Agreement: 

 

	 	(a)	[***], and [***] and [***] of any [***] in order to make, have made, use, offer for sale, sell, have sold, import, distribute, have distributed Products in the
Territory, it being understood and acknowledged by BGM that Abbott has not performed a freedom to operate analysis with respect to the Patent Rights and its ability to commercialize the Products; and 

  

	 	(b)	The [***] identified in paragraph (a) have [***] that Abbott [***] or [***] related to [***], to [***] from [***], [***] to [***]. 

  

	8.4	Debarment and Exclusion. BGM represents and warrants that neither it, nor any of its employees or agents working on the subject matter of this Agreement, has
ever been, is currently, or is the subject of a proceeding that could lead to it becoming, as applicable, a Debarred Entity or Individual, an Excluded Entity or Individual or a Convicted Entity or Individual. BGM further covenants, represents and
warrants that if, during the Term of this Agreement, it, or any of its employees or agents working on Abbott’s behalf, becomes or is the subject of a proceeding that could lead to that Party becoming, as applicable, a Debarred Entity or
Individual, an Excluded Entity or Individual or a Convicted Entity or Individual, BGM shall immediately notify Abbott, and Abbott shall have the right to immediately terminate this Agreement. This provision shall survive termination or expiration of
this Agreement. For purposes of this provision, the following definitions shall apply: 

  

	 	(a)	A “Debarred Individual” is an individual who has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from providing services
in any capacity to a person that has an approved or pending drug product application. 

  

	 	(b)	 A “Debarred Entity” is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. §335a
(a) or (b) from submitting or

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 13 

 
assisting in the submission of any abbreviated drug application, or a subsidiary or Affiliate of a Debarred Entity. 
  

	 	(c)	An “Excluded Individual” or “Excluded Entity” is (i) an individual or entity, as applicable, who has been excluded, debarred,
suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or (ii) is an individual or
entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration (GSA).

  

	 	(d)	A “Convicted Individual” or “Convicted Entity” is an individual or entity, as applicable, who has been convicted of a criminal offense
that falls within the ambit of 42 U.S.C. §1320a – 7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible. 

  

	8.5	Limitation on Warranties. NEITHER PARTY MAKES ANY OTHER WARRANTIES OTHER THAN THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, AND EXCEPT AS STATED IN THIS
AGREEMENT, THERE SHALL BE NO IMPLIED OR STATUTORY WARRANTIES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 

  

	8.6	Additional Representation and Warranty. Each Party represents and warrants to the other Party as of the Execution Date, that the execution, delivery and
performance by it of this Agreement and its compliance with the terms and provisions thereof does not and will not conflict with or result in a breach of any other material agreement or relationship, which breach will materially and adversely affect
such Party’s ability to perform its obligations hereunder. 

 ARTICLE 9. INDEMNIFICATION

  

	9.1	BGM Indemnification. BGM shall indemnify, defend and hold Abbott and its Affiliates and their officers, directors, employees and representatives collectively,
(“Abbott Indemnitees”) harmless from and against any and all losses, damages, demands, fees, expenses, fines, penalties and costs (including reasonable attorney’s fees) (hereinafter, “Losses”) to the extent
that such Losses arise out of, relate to or are in connection with claims, causes of action, suits or proceedings of Third Parties (hereinafter “Claims”) resulting from: (a) the material breach of BGM’s warranties,
representations or covenants set forth in this Agreement; (b) gross negligence or willful misconduct on the part of BGM, including its employees, agents or representatives. 

  

	9.2	 Abbott Indemnification. Abbott shall indemnify, defend and hold BGM and its Affiliates and their officers, directors, employees, and representatives
(collectively, “BGM

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 14 

 
Indemnitees”) harmless from and against any and all Losses, to the extent that such Losses arise out, relate to or are in connection with Claims resulting from: (a) the material
breach of Abbott’s warranties, representations or covenants set forth in this Agreement; (b) gross negligence or willful misconduct on the part of Abbott, including its employees, agents or representatives, or (c) the use, sale or
import by Abbott or any of its Affiliates, distributors or agents, of any Product or the use of any Product by or in the diagnosis or treatment of any Third Party. 
  

	9.3	Offsetting Claims. With respect to any Claim for which BGM has an obligation to any Abbott Indemnitee pursuant to Section 9.1 and Abbott has an obligation
to any BGM Indemnitee pursuant to Section 9.2, each Party shall indemnify each of the other Party’s Indemnitees for its Losses to the extent of its responsibility, relative to the other Party, for the facts underlying the Claim.

  

	9.4	Cooperation. With respect to any Claim for which a Party seeks indemnification (“Indemnitee”) from any other Party
(“Indemnitor”) under this Article 9, the Indemnitee shall: (a) promptly advise the Indemnitor in writing of any Claim within thirty (30) days after the Indemnitee received notice of such Claim, or within such period of
time so as not to materially prejudice the right of the Indemnitor with regard to the defense of such Claim (whichever time period is shorter); and (b) assist the Indemnitor and its representatives in the investigation and defense of any Claim
for which indemnification is provided. The Indemnitor shall defend, and control the defense of, any such Claim, and shall not offer to settle, settle or otherwise compromise such Claim without the Indemnitee’s prior written consent (which
consent will not be unreasonably withheld), unless such settlement fully releases the Indemnitee without any liability, loss, cost or obligation. 

 ARTICLE 10. CONFIDENTIALITY AND PUBLIC ANNOUNCEMENTS 
  

	10.1	Confidentiality. The Parties acknowledge and agree that during the Term, each of them and their Affiliates may exchange Confidential Information, and the
disclosure and use of any such Confidential Information shall be governed by the provisions of this Section 10.1. Each Party (“Receiving Party”) shall use the Confidential Information of the other Party (“Disclosing
Party”) only for the purpose of the activities contemplated by this Agreement and shall not disclose such Confidential Information to a Third Party except in accordance with the provisions of this Agreement. The Parties shall ensure that
their Affiliates keep all Confidential Information exchanged hereunder confidential in accordance with the provisions hereof as though the Affiliates were parties hereto. This provision shall remain in effect for a period of five (5) years
after termination or expiration of this Agreement for all Confidential Information excluding Trade Secrets (as defined in Section 10.2). Trade Secrets shall be kept confidential by the Receiving Party (as defined in Section 10.2 hereof)
according to the terms set forth in Section 10.2. The provisions of this Section 10.1 shall not apply to any information which: 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 15 

	 	(a)	Is known to the Receiving Party before receipt thereof under this Agreement, as evidenced by the Receiving Party’s written records; 

  

	 	(b)	Is disclosed to the Receiving Party without restriction by a Third Party (as hereinafter defined) that is, to the Receiving Party’s knowledge, not under an
obligation of nondisclosure to the Disclosing Party; 

  

	 	(c)	Is or becomes part of the public domain other than through a breach of this Agreement by the Receiving Party; 

  

	 	(d)	Is independently developed by or for the Receiving Party without use of the Disclosing Party’s Confidential Information, as evidenced by the Receiving Party’s
written records; 

  

	 	(e)	In any case in which it is disclosed by the Receiving Party with the Disclosing Party’s prior written approval; or 

  

	 	(f)	In any case in which it is required by law to be disclosed; provided, that in such instance the Receiving Party will provide the Disclosing Party with at least
ten (10) business days notice prior to making the required disclosure (or as much notice as possible if the disclosure is required to be made in less than ten (10) business days) in order to allow the Disclosing Party to review such
disclosure and to take appropriate measures to protect the confidentiality of its Confidential Information; provided further, that to the extent the Disclosing Party is unsuccessful in protecting against disclosure of its Confidential
Information, the Receiving Party shall only disclose such Confidential Information to the minimum extent required to comply with applicable law. 

  

	10.2	Handling of Trade Secrets. During the course of its performance hereunder, a Party (the “Disclosing Party”) may desire or be requested to
disclose Confidential Information to the other Party (the “Receiving Party”), which the Disclosing Party considers a trade secret (“Trade Secret”). In such event, the Disclosing Party first shall inform the
Receiving Party, on a non-confidential basis, of the general nature of the Trade Secret information. The Receiving Party shall have ten (10) days to decide whether it wishes to have such Trade Secrets disclosed to it and to inform the
Disclosing Party in writing that it wishes to receive such a disclosure. Any Trade Secrets so disclosed between the Parties shall be marked “Trade Secret,” and the Receiving Party shall not disclose or use such Trade Secret for the Term
and thereafter except as expressly permitted under this Agreement. In the event the Disclosing Party discloses the Trade Secrets to the Receiving Party without written approval of the Receiving Party and/or without appropriately marking such
information as “Trade Secret” that trade secret shall be handled as Confidential Information under Section 10.1. 

  

	10.3	 Confidential Treatment. Each Party shall seek confidential treatment for the terms and conditions of this Agreement to the fullest extent
permitted by the SEC and any other

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 16 

 
governmental agency or self-regulatory organization to which a Party provides a copy of this Agreement. Prior to seeking confidential treatment from the SEC or any other governmental agency or
self-regulatory organization for any such document, the filing Party shall provide the other Party and the other Party’s counsel with a copy of the proposed filing showing the filing Party’s proposed redactions of the document, and shall
consult with the other Party and the other Party’s counsel and provide them with a reasonable opportunity to request the inclusion of specified provisions or redactions in any request for confidential treatment. 
  

	10.4	Permitted Disclosure. Notwithstanding Section 10.1, disclosure of the Disclosing Party’s Confidential Information and of this Agreement and the terms
hereof may be made by the Receiving Party: (I) (a) on a need-to-know basis to the Receiving Party’s legal and financial advisors; (b) as reasonably necessary in connection with an actual or potential (i) debt or equity
financing of the Receiving Party or (ii) Change of Control involving the Receiving Party; and (c) to any Third Party to enable the Receiving Party to exercise its rights and perform its obligations under this Agreement; if, in the case of
clauses (a) (except with respect to disclosures to the Receiving Party’s legal advisors), (b) and (c), the person or entity receiving such Confidential Information of the Disclosing Party is bound by written or professional
obligations substantially as restrictive as those contained in Section 10.1, and (II) as reasonably necessary for the Receiving Party to file, prosecute and maintain Patent Rights, or to file, prosecute or defend litigation against Third
Parties related to Patent Rights, in accordance with this Agreement; provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available.

  

	10.5	Press Announcements. The terms of this Agreement shall be considered Confidential Information. As soon as reasonably practicable after the Effective Date, the
Parties shall issue a joint public announcement of the execution of this Agreement in a form agreed upon by the Parties and approved through their respective corporate approval processes. Neither Party shall make any public announcement concerning
this Agreement, nor make any public statement which includes the name of any other Party or any of its Affiliates, or otherwise use the name of any of the other Parties or any of their Affiliates in any public statement or document, except as may be
required by law or judicial order, without the written consent of each of the other Parties, which written consent shall not be withheld unreasonably. Once a Party has consented to public disclosure of its Confidential Information pursuant to this
Section 10.5, the other Party may make subsequent public disclosures of the same Confidential Information without further consent. 

 ARTICLE 11. TERM AND TERMINATION 
  

	11.1	 Term; Termination for Breach. This Agreement shall commence on the Effective Date, and unless terminated early pursuant to the provisions of
this Agreement, shall expire on the expiration date of the last-to-expire patent in Patent Rights that covers Product (“Term”). Either Party may terminate this Agreement upon sixty (60) days written notice

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 17 

 
to the other Party if the other Party materially breaches this Agreement and such breach is not cured within such sixty (60) day period. 
  

	11.2	Abbott Termination. Abbott shall have the right to terminate this Agreement on thirty (30) days written notice to BGM without further payments due to BGM,
other than payment obligations that have accrued prior to termination, if Abbott determines that any of the following occurs: 

  

	 	(a)	Product does [***], or 

  

	 	(b)	Product does [***], or 

  

	 	(c)	Product does [***], or 

  

	 	(d)	[***], or 

  

	 	(e)	Abbott [***], or 

  

	 	(f)	Product [***], or 

  

	 	(g)	The [***] in the US, or 

  

	 	(h)	Galectin-3 is [***], or 

  

	 	(i)	[***]. 

  

	11.3	Consequences of Termination. If Abbott, in its sole discretion, voluntarily, and for reasons within its control (i.e., for reasons other than those set forth in
Section 11.2), discontinues the Product’s development program pursuant to the Umbrella Agreement, or discontinues the sale of Products as contemplated by this Agreement, then Abbott may terminate this Agreement upon thirty (30) days
written notice to BGM and, in its sole discretion, either: (a) shall pay BGM the amount that BGM paid FDI to develop the Product pursuant to the Umbrella Agreement; or (b) allow BGM to sell Products pursuant to the terms and conditions of
a distribution arrangement negotiated in good faith between the Parties. 

  

	11.4	Accrued Rights and Obligations. The termination or expiration of this Agreement shall not relieve any Party of any obligation arising under this Agreement which
shall have accrued prior to such expiration or termination. 

  

	11.5	 Survival. The following Articles and Sections shall survive the expiration or termination of this Agreement: Articles 1, 8, 9, 10 and 11 and
Sections 3.10, 3.11, 3.12, 6.1, 6.2, 6.5, 7.1.4 and 7.1.5. All provisions that survive termination, that are irrevocable or that arise due to termination shall survive in accordance with their terms. Any provisions of this Agreement contemplated by
their terms to pertain to a period of time following

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 18 

 
termination or expiration of this Agreement shall survive only for the specified period of time. 
 ARTICLE 12. MISCELLANEOUS 
  

	12.1	Force Majeure. No Party shall be liable for loss, damage, detention or delay resulting from any cause whatsoever beyond its reasonable control or resulting from
a force majeure, including, without limitation, fire, flood, strike, lockout, civil or military authority, insurrection, war, embargo, container or transportation shortage or delay of suppliers, and delivery dates shall be extended to the extent of
any delays resulting from the foregoing or similar causes. The Party so affected shall give prompt notice to the other Party of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as
reasonably possible. The party giving such notice shall be excused from such of its obligations hereunder for so long as it is so disabled or for thirty (30) days after notification to the other Party, whichever is longer; provided,
however, that such affected Party commences and continues to take reasonable and diligent actions to cure such cause. Notwithstanding the foregoing, nothing in this Section 12.1 shall excuse or suspend the obligation to make any
payment due hereunder in the manner and at the time provided. 

  

	12.2	Assignment. No Party hereto shall have the right to assign any of its rights or obligations under this Agreement to a Third Party without the prior written
consent of each of the other Party, which consent shall not be withheld unreasonably; provided, however, that without such consent, a Party may assign this Agreement in whole or in part to an Affiliate of the assigning Party or in
whole, but not in part, to any purchaser of all or substantially all of its assets to which this Agreement relates or to any successor corporation resulting from any Change of Control. 

  

	12.3	Binding Effect. This Agreement shall be binding upon and inure to the benefit of each Party hereto and its successors and assigns. 

  

	12.4	Relationship of the Parties. The relationship of the Parties hereunder is that of independent contractors. Nothing contained in this Agreement shall be construed
so as to constitute the Parties as partners, joint ventures or agents of the other. No Party or its Affiliates has any express or implied right or authority under this Agreement to assume or create any obligations or make any representations or
warranties on behalf of or in the name of the other Party or any of such other Party’s Affiliates. 

  

	12.5	Amendments. Except as otherwise expressly provided herein, neither this Agreement nor any provision hereof may be amended except by a written instrument signed
by each Party. 

  

	12.6	Waivers. Any waiver by any Party hereto of any rights arising from a breach of any covenants or conditions of this Agreement shall not be construed as a
continuing waiver of other breaches of the same nature or other covenants or conditions of this Agreement. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 19 

	12.7	Notices. All written notices and other communications between the Parties which shall or may be given pursuant to this Agreement shall be deemed to have been
sufficiently given when delivered by personal service or sent by registered or certified mail return receipt requested, overnight delivery service providing evidence of delivery, or confirmed facsimile, to the recipient addressed as follows:

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 20 

			
	 If to Abbott:
	  	With a copy to:
		
	 Abbott Laboratories
 100 Abbott Park Road
 Abbott Park, IL 60064-6095
 Attn: [***]
 [***]
 Facsimile: [***]
	  	 Abbott Laboratories
 100
Abbott Park Road
 Abbott Park, IL 60064-6049
 Attn: [***]
 [***]
 Facsimile:
[***]

		
	 If to BGM :
	  	
		
	 BG Medicine, Inc.
 610 Lincoln Street North
 Waltham, MA 02451
 Tel: 781-890-1199
 Fax: 781-895-1119
 Attn: President & CEO
	  	

 All such communications shall be deemed to be effective on the day on which
personally served, or, if sent by registered mail, on the fourth day following the date presented to the postal authorities for delivery to the other Party (the cancellation date stamped on the delivery or the envelope being evidence of the date of
such delivery), or if by overnight delivery or facsimile, on the delivery or the facsimile date. Either Party may give to the other Party written notice of change of address, in which event any communication shall thereafter be given to such other
Party as above provided at such changed address. 
  

	12.8	Applicable Legal Requirements. Each Party shall comply with all applicable legal requirements and shall not be required to perform or omit to perform any act
required or permitted under this Agreement if such performance or omission would violate the provisions of any such applicable legal requirement. 

  

	12.9	Further Assurances. Subject to the terms and conditions of this Agreement, each Party shall cooperate with the other Party to take, or cause to be taken, all
actions and to do, or cause to be done, all things necessary or desirable under applicable laws and regulations to consummate the transactions contemplated by this Agreement. 

  

	12.10	Entire Agreement; Conflict in Terms. This Agreement is the sole understanding and agreement between the Parties hereto with respect to the subject matter hereof
and supersedes all other prior agreements and understandings with respect to the subject matter hereof. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 21 

	12.11	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, excluding its conflict of laws provisions.

  

	12.12	Alternative Dispute Resolution. Any dispute or claim arising out of or in connection with this Agreement (unless otherwise set forth herein) shall be finally
settled by Alternative Dispute Resolution (“ADR”) in accordance with the process set forth on Exhibit 12.12. 

  

	12.13	Interpretation. Where the context hereto requires, the singular number shall be deemed to include the plural and vice-versa. The headings of the Articles,
Sections and Subsections of this Agreement have been added for the convenience of the Parties and shall not be deemed a part hereof or used in the interpretation of this Agreement. In any context herein, “or” is not exclusive;
“including” and “include” are not exclusive and are deemed to be followed by the words “without limitation.” 

  

	12.14	Severability. If any provision of this Agreement is finally held to be invalid, illegal or unenforceable by a court or agency of competent jurisdiction, that
provision shall be severed or shall be modified by the Parties so as to be legally enforceable (and to the extent modified, it shall be modified so as to reflect, to the extent possible, the intent of the Parties) and the validity, legality and
enforceability of the remaining provisions shall not be affected or impaired in any way. 

  

	12.15	Counterparts. This Agreement may be executed in two (2) original counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. 

  

	12.16	Mutual Drafting. This Agreement is the joint product of the Parties, and each provision hereof has been subject to the mutual consultation, negotiation and
agreement of the Parties and each Party’s respective legal counsel and advisors, and any rule of construction that a document shall be interpreted or construed against the drafting Party shall not be applicable with respect to this Agreement.

  

	12.17	Change of Control. In the event of a Change of Control, BGM shall assign all of its obligations under the Umbrella Agreement and this Agreement to the surviving
entity in any merger or consolidation or to any entity to which it transfer all or substantially all of its business to which this Agreement relates. By such assignment, the acquirer shall be bound by all the terms and provisions of this Agreement
and the Umbrella Agreement, and the acquirer shall assume all the obligations of BGM under this Agreement and the Umbrella Agreement. 

 (Remainder of Page Intentionally Left Blank) 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 22 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be executed by its duly authorized
representative. 
  

									
	ABBOTT LABORATORIES	 		 	BG MEDICINE, INC.
					
	By:	 	/s/    Michael J. Warmuth        	 		 	By:	 	/s/    Pieter Muntendam        
		 	Michael J. Warmuth	 		 		 	Pieter Muntendam
					
	Title:	 	Senior Vice President	 		 	Title:	 	President & CEO
		 	President, Abbott Diagnostics Division	 		 		 	

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 23 

 Exhibit 1.12 
 Patent Rights 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 

 

 CONFIDENTIAL 
 BG MEDICINE INC. PATENTS and PATENT APPLICATIONS RELATING TO GALECTIN-3 – 
 Status on November 9, 2009 
  

											
	PATENT TITLE	  	DOCKET No.        	  	COUNTRY         	 	SERIAL or PATENT      
No.      	 	FILING DATE      	  	STATUS    
	 	 	 	 	 	 
	 [***]
	  	[***]        	  	[***]        	 	[***]    	 	[***]    	  	[***]    
	 	 	 	 	 	 
	 [***]
	  	[***]        	  	[***]        	 	[***]    	 	[***]    	  	[***]    
	 	 	 	 	 	 
	 [***]
	  	[***]        	  	[***]        	 	[***]    	 	[***]    	  	[***]    
	 	 	 	 	 	 
	 [***]
	  	[***]        	  	[***]        	 	[***]    	 	[***]    	  	[***]    
	 	 	 	 	 	 
	 [***]
	  	[***]        	  	[***]        	 	[***]    	 	[***]    	  	[***]    

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Exhibit 4.4 
 BGM Promotional Activities 
 BGM agrees to use Commercially
Reasonable Efforts, as set forth in Section 4.4, to accomplish the following activities in support of Galectin-3 marker development. These activities shall be reviewed at the quarterly Steering Committee meetings and adjusted by mutual written
agreement of the Parties. 
  

	1)	Develop and execute a [***] to [***] of Galectin-3 [***] and [***] in the [***]. Activities shall include: 

  

	 	a.	Recruitment of [***] of Galectin-3 [***] to [***] of Galectin-3 products. 

	 	b.	[***] or [***] that focus on: i) the role of Galectin-3 in cardiovascular disease, ii) its potential use in the [***] of [***] or [***], and iii) its [***] and [***].

	 	c.	Develop and execute a [***] to [***]. Activities may include: 

 i) Develop and [***] a [***] for Galectin-3. 
 ii) Develop and [***] a [***]. 
 iii) Create a comprehensive Galectin-3 [***] for [***] which have been [***] and [***] to [***] to [***]. 
  

	2)	Create and execute a [***]. Activities shall include: 

  

	 	a.	Develop, test and refine [***] and [***]. 

	 	b.	Translate relevant [***] into [***]. 

	 	c.	Create, train and deploy a [***] in [***] for [***]. 

  

	3)	Develop and implement a [***] for [***]. Activities shall include: 

  

	 	a.	Conduct a [***] in the [***] that [***] for Galectin-3 the [***] of the Product, the [***] and [***], the key [***] and [***], the [***] and [***] to [***].

	 	b.	Develop and execute a [***] in the [***]. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit 4.4 

 Exhibit 5.1 
 Clinical Studies and Clinical Indications 
 BGM use
Commercially Reasonable Efforts to perform the following activities in support of Galectin-3 clinical development. These activities shall be reviewed at the quarterly Steering Committee meetings and adjusted by mutual written agreement of the
Parties. 
  

	 	1)	Conduct clinical studies and partnerships [***], [***] and [***] of Galectin-3 in the following areas. In addition, whenever possible provide sufficient [***] from
[***] to [***] to allow for submission for additional clinical indications 

  

	 	a.	Heart Failure [***]: Studies reasonably anticipated to show that Galectin-3 [***] in [***] of Heart Failure patients and provides additional [***] such as [***],
and [***]. 

  

	 	b.	[***] Selection: Studies reasonably anticipated to show the role of Galectin-3 in [***] or other [***] in [***] of patients that are not currently considered for
these [***]. 

  

	 	c.	[***] Studies: Studies reasonably anticipated to show that current [***], [***], can be [***] for patients using Galectin-3 levels. Studies reasonably
anticipated to show that Galectin-3 may be useful in [***] for [***]. 

  

	 	d.	[***] Studies: Studies reasonably anticipated to show the [***] and [***] of using Galectin-3, for example, like the [***] on the role of Galectin-3 [***] in the
[***] of HF patients. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit 5.1 

 Exhibit 12.12 
 Alternative Dispute Resolution 
 The Parties
recognize that from time to time a dispute may arise relating to any Party’s rights or obligations under this Agreement. The Parties agree that any such dispute shall be resolved by the Alternative Dispute Resolution (“ADR”)
provisions set forth in this Exhibit, the result of which shall be binding upon the Parties. 
 To begin the ADR process, a
Party first must send written notice of the dispute to the other Party for attempted resolution by good faith negotiations between their respective presidents (or their designees) of the affected subsidiaries, divisions, or business units within
twenty-eight (28) days after such notice is received (all references to “days” in this ADR provision are to calendar days). If the matter has not been resolved within twenty-eight (28) days after the notice of dispute, or if the
Parties fail to meet within such twenty-eight (28) days, either Party may initiate an ADR proceeding as provided herein. The Parties shall have the right to be represented by counsel in such a proceeding. 
 1. To begin an ADR proceeding, a Party shall provide written notice to the other Party of the issues to be resolved by ADR. Within fourteen
(14) days after its receipt of such notice, the other Party may, by written notice to the Party initiating the ADR, add additional issues to be resolved within the same ADR. 
 2. Within twenty-one (21) days following the initiation of the ADR proceeding, the Parties shall select a mutually acceptable
independent, impartial and conflicts-free neutral to preside in the resolution of any disputes in this ADR proceeding. If the Parties are unable to agree on a mutually acceptable neutral within such period, each Party will select one independent,
impartial and conflicts-free neutral and those two neutrals will select a third independent, impartial and conflicts-free neutral within ten (10) days thereafter. None of the neutrals selected may be current or former employees, officers,
directors, consultants or attorneys of any Party, its subsidiaries or Affiliates. 
 3. No earlier than twenty-eight
(28) days or later than fifty-six (56) days after selection, the neutral(s) shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding shall take place at a location agreed upon by the Parties. If the
Parties cannot agree, the neutral(s) shall designate a location other than the principal place of business of either Party or any of their subsidiaries or Affiliates. 
 4. At least seven (7) days prior to the hearing, each Party shall submit the following to the other Party and the neutral(s): 
 (a) a copy of all exhibits on which such Party intends to rely in any oral or written presentation to the neutral;

 (b) a list of any witnesses such Party intends to call at the hearing, and a short summary of the anticipated
testimony of each witness; 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (c) a proposed ruling on each issue to be resolved, together with a request
for a specific damage award or other remedy for each issue. The proposed rulings and remedies shall not contain any recitation of the facts or any legal arguments and shall not exceed one (1) page per issue. The Parties agree that neither side
shall seek as part of its remedy any punitive damages. 
 (d) a brief in support of such Party’s proposed
rulings and remedies, provided that the brief shall not exceed twenty (20) pages, without agreement of the Parties. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. 
 Except as expressly set forth in subparagraphs 4(a) – 4(d), no discovery shall be required or permitted by any means,
including depositions, interrogatories, requests for admissions, or production of documents. 
 5. The hearing shall be
conducted on no more than three (3) consecutive days, as determined at least ten (10) days before the hearing by the neutral(s), and shall be governed by the following rules: 
 (a) Each Party shall be entitled to no more than six (6) hours hearing time, as determined at least ten (10) days
before the hearing by the neutral(s), to present its case. The neutral(s) shall determine whether each Party has had the hours to which it is entitled. 
 (b) Each Party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal testimony, documents or other evidence, to cross-examine witnesses, and to make a closing
argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-examination time shall be charged against the party conducting the cross-examination. 
 (c) The Party initiating the ADR shall begin the hearing and, if it chooses to make an opening statement, shall address not
only issues it raised but also any issues raised by the responding Party. The responding Party, if it chooses to make an opening statement, also shall address all issues raised in the ADR. Thereafter, the presentation of regular and rebuttal
testimony and documents, other evidence, and closing arguments shall proceed in the same sequence. 
 (d) Except
when testifying, witnesses shall be excluded from the hearing until closing arguments. 
 (e) Settlement
negotiations, including any statements made therein, shall not be admissible under any circumstances. Affidavits prepared for purposes of the ADR hearing also shall not be admissible. As to all other matters, the neutral(s) shall have sole
discretion regarding the admissibility of any evidence. 
 6. Within seven (7) days following completion of the hearing,
each Party may submit to the other Party and the neutral(s) a post-hearing brief in support of its proposed rulings

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
and remedies, provided that such brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. This page limitation shall apply regardless of the number of issues
raised in the ADR proceeding. 
 7. The neutral(s) shall rule on each disputed issue within fourteen (14) days following
completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one of the Parties on each disputed issue but may adopt one Party’s proposed rulings and remedies on some issues and the other Party’s
proposed rulings and remedies on other issues. The neutral(s) shall not issue any written opinion or otherwise explain the basis of the ruling. 
 8. The neutral(s) shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and expenses of the prevailing Party (including all expert witness fees and
expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: 
 (a) If the neutral(s) rule(s) in favor of one Party (ies) on all disputed issues in the ADR, the losing Party (ies) shall pay 100% of such fees and expenses. 
 (b) If the neutral(s) rule(s) in favor of one Party (ies) on some issues and the other Party (ies) on other issues, the
neutral(s) shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the Parties. The neutral(s) shall allocate fees and expenses in a way that bears a reasonable relationship to the outcome of
the ADR, with the Party (ies) prevailing on more issues, or on issues of greater value or gravity, recovering a relatively larger share of its (their) legal fees and expenses. 
 9. The rulings of the neutral(s) and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be
entered as a final judgment in any court having jurisdiction. 
 10. Except as provided in paragraph 9 or as required by law,
the existence of the dispute, any settlement negotiations, the ADR hearing, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed Confidential Information. The neutral(s) shall have the
authority to impose sanctions for unauthorized disclosure of Confidential Information. 
  

	11.	All ADR hearings shall be conducted in the English language. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.Product License and Collaboration Agreement

 Exhibit 10.5 
 PRODUCT LICENSE AND COLLABORATION AGREEMENT 
 This Product
License and Collaboration Agreement (this “Agreement”) is made and entered into as of this 4 day of May, 2007 (the “Effective Date”), by and between (i) BG Medicine, Inc., a Delaware corporation
(“BGM”), (ii) ACS Biomarker B.V. i.o. (“ACSB”), a corporation to be established by the University of Maastricht (the “University”), BioMedbooster B.V., a corporation organized under the laws of
The Netherlands (“BioMedbooster”), Yigal Pinto, Mat Daemen, Tilman Hackeng and Marcel Kannekens, and (iii) solely for purposes of Section 3.04 hereof, the University and BioMedbooster. 
 WHEREAS, the University and BioMedbooster have committed to grant to ACSB certain Intellectual Property Rights (as defined below) and
capabilities in the field of cardiac disease markers, in particular in the area of heart failure; 
 WHEREAS, BGM owns advanced
proteomic and metabolomic capabilities that are applied for biomarker discovery and validation; and 
 WHEREAS, BGM and ACSB
(each, a “Party”), are interested in BGM’s licensing certain intellectual property rights owned by ACSB on an exclusive basis in exchange for certain royalty payments, and in pursuing an alliance for the detection and
validation of markers in congestive heart failure and other areas; 
 NOW, THEREFORE, in consideration of the mutual premises
and covenants herein contained and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties and the other parties hereto hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 As used herein, the following terms shall have the following meanings: 
 (a) “ACSB Marker Notice” shall have the meaning set forth in Section 4.02(b). 
 (b) “Affiliate” shall mean, with respect to a Person, any (i) corporation, firm, partnership or other entity
which directly or indirectly controls such Person, (ii) corporation, firm, partnership or other entity which is controlled by or is under common control with such Person, (iii) corporation, firm, partnership or other entity which is
controlled by a corporation, firm, partnership or other entity as defined in (i) above, or (iv) corporation, firm, partnership or other entity which is controlled by a corporation, firm, partnership or other entity as defined in
(iii) above. For purposes of this definition, “control” means ownership, directly or through one or more Affiliates, of (a) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors,
in the case of a corporation, (b) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity, status as a general partner in any partnership, or (c) any other arrangement whereby a Party
controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity. 
 (c) “BGM Project Notice” shall have the meaning set forth in Section 4.01. 
 Portions of this
Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (d) “CARIM” shall mean the Cardiovascular Research Institute
Maastricht. 
 (e) “Confidential Information” shall mean all trade secrets, proprietary information,
know-how, data, designs, specifications, processes, customer lists and other technical or business information (and any tangible evidence, record or representation thereof), including without limitation any idea, improvement, invention, innovation,
development, concept, technical data, design, formula, device, pattern, sequence, method, process, composition of matter, product specification or design, plan for a new or revised product, sample, compilation of information, or work in process, or
parts thereof, and any and all revisions and improvements relating to any of the foregoing (in each case whether or not reduced to tangible form). 
 (f) “Field of Interest” shall mean such fields as BGM and ACSB shall mutually agree and set forth in any Licensing Addendum. 
 (g) “First Commercial Sale” of a Subject Product shall mean the first sale of such Subject Product by BGM, its
Affiliate or its Sublicensee(s), for end use or consumption, after all required Regulatory Approvals have been granted by the applicable Regulatory Authorities. 
 (h) “First Look Right” shall have the meaning set forth in Section 4.01. 
 (i) “GAAP” shall mean U.S. generally accepted accounting principles, consistently applied. 
 (j) “Intellectual Property Rights” shall mean any and all rights in Intellectual Property. 
 (k) “Intellectual Property” shall mean all patents, patent applications, the right to apply for patents, trademarks, trademark applications, service marks, tradenames, copyrights,
trade secrets, licenses, sublicenses, domain names, mask works, information and other proprietary rights and processes recognized anywhere in the world. 
 (l) “Licensing Addendum” shall have the meaning set forth in Section 2.01. 
 (m) “Marker” shall mean a biochemical characteristic that is objectively measured and evaluated as an indicator of normal biologic or pathogenic processes or pharmacological
responses to a therapeutic intervention. 
 (n) “Net Sales” shall mean, with respect to a particular
Subject Product, the actual gross amount invoiced by BGM or its Affiliates for commercial sales of such Subject Product after deducting, in accordance with GAAP, the following: 
 (i) trade, cash and quantity discounts reasonably consistent with industry standards; 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 2 

 (ii) credits or allowances for damaged or spoiled product, returns,
recalls or rejections of products, including allowance for breakage or spoilage; 
 (iii) sales, value
added, excise or other direct taxes, and freight, postage, shipping and transportation insurance charges and additional transportation, custom duties, and other governmental charges on the Subject Product; and 
 (iv) chargebacks, rebates or similar payments or credits directly related to the Subject Product consistent with
reasonable industry standards granted to managed health care organizations, wholesalers, distributors, buying groups, retailers, health care insurance carriers, pharmacy benefit management companies, health maintenance organizations or other
institutions or health care organizations or to federal, state/provincial, local and other governments, their agencies and purchasers and reimbursers. 
 Sales or other transfers between BGM and its Affiliates shall be excluded from the computation of Net Sales and no payments will be payable on such sales or transfers except where such Affiliates are end
users, but Net Sales shall include the subsequent sales to Third Parties by such Affiliates. Where an Affiliate is the end user, Net Sales shall be deemed to be equal to the average per-unit price charged to Third Parties for the same Subject
Product during the relevant calendar half-year multiplied by the number of units sold or transferred to the Affiliate during such calendar half-year. 
 (o) “Person” shall mean any individual, corporation, partnership, limited liability company, firm, joint venture, association, joint-stock company, trust, unincorporated organization
or other entity. 
 (p) “Regulatory Approval” means all approvals and clearances of Regulatory Authorities
(including where applicable pricing and reimbursement approvals required for marketing authorization), product and/or establishment licenses, registrations or authorizations necessary for the manufacture, use, storage, import, export, transport and
marketing and/or sale of a Subject Product in a particular jurisdiction. 
 (q) “Regulatory Authority”
shall mean the FDA in the U.S., and the EMEA or any agency in the European Union and any health regulatory authority(ies) in any other country(ies) that is equivalent to the FDA and holds responsibility for granting Regulatory Approval for a Subject
Product in such country(ies), and any successor(s) thereto having substantially the same functions. 
 (r) “Right
of First Offer” shall have the meaning set forth in Section 4.02. 
 (s) “Royalty
Statement” shall have the meaning set forth in Section 2.02(g). 
 (t) “Subject BGM
Project” shall mean any Marker-related research or development project initiated by BGM within the Field of Interest for which ACSB, CARIM or the University could, in the reasonable judgment of BGM, be a qualified investigator or
collaborator. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 3 

 (u) “Subject IP” shall mean any Intellectual Property Rights
identified as Subject IP in a Licensing Addendum. 
 (v) “Subject Markers” shall have the meaning set
forth in Section 4.02. 
 (w) “Subject Products” shall have the meaning set forth in
Section 2.02(a)(i). 
 (x) “Sublicense Non-Royalty Payments” shall mean any payments received
by BGM from Sublicensees as consideration for the grant of a Sublicense, including without limitation, license fees, technology fees, milestone payments and license maintenance fees, but excluding amounts received by BGM (i) as Sublicense
Royalty Payments; (ii) as dollar-for-dollar reimbursement for or prepayment of BGM’s research and development expenses incurred in connection with the applicable Subject IP, as determined in accordance with GAAP; or (iii) for a
Sublicensee’s purchase of securities of BGM. 
 (y) “Sublicense Royalty Payments” shall mean payments
received by BGM from Sublicensees as consideration for the grant of such sublicense that are based on net sales of Subject Products by such Sublicensee. 
 (z) “Sublicense” shall mean a sublicense to Subject IP granted by BGM, as well as any sublicense granted by the sublicensee of such Sublicense. 
 (aa) “Sublicensee” shall mean any Person to whom BGM grants a Sublicense, as well as any entity to which such Person
grants a Sublicense 
 (bb) “Sublicensing Income” shall, with respect to any particular Subject IP, all
Sublicense Non-Royalty Payments and Sublicense Royalty Payments generated from such Subject IP. 
 (cc) “Third
Party(ies)” shall mean a Person who or which is neither a Party nor an Affiliate of a Party. 
 (dd) “University” shall mean the University of Maastricht. 
 (ee) “Valid
Claim” means a claim of an issued and unexpired patent, which has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and which has not been disclaimed or
surrendered through reissue or disclaimer. 
 ARTICLE II 
 LICENSE, ROYALTIES AND COLLABORATION 
 Section 2.01 License of Subject IP. BGM shall have, and ACSB hereby grants to BGM, a license to any and all Intellectual Property Rights as may be agreed by the Parties and set forth from time to time in one or more
addenda to this Agreement on the terms set forth

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 4 

 
herein and on such additional terms as may be set forth in such addenda. Any such Intellectual Property Rights are sometimes hereinafter referred to as “Subject IP,” and any such
addendum is sometimes hereinafter referred to as a “Licensing Addendum.” The Parties shall use the form attached hereto as Exhibit A as the template for each Licensing Addendum. The license so granted with respect to the
Subject IP identified in any particular Licensing Addendum (each, a “License”) shall be on the following terms, except as otherwise provided in such Licensing Addendum: 
 (a) Exclusivity. Such License shall be exclusive or non-exclusive as set forth in the applicable Licensing
Addendum; provided, however, that the University, ACSB, BioMedbooster and each of their respective Affiliates shall have a limited, non-exclusive license, without the right to grant sublicenses, to use any Subject IP solely for internal
research and teaching purposes. 
 (b) Field of Use. Such License shall entitle BGM to use and
exploit the applicable Subject IP for the purpose or purposes as set forth in the applicable Licensing Addendum. 
 (c) Term. Such License shall be for the term specified in the applicable Licensing Addendum. 
 (d) Sublicensing. Such License shall include the right to grant Sublicenses as set forth in the applicable Licensing Addendum. 
 (e) Territory. Such License shall be valid in the countries specified in the applicable Licensing Addendum. 
 (f) Royalties. BGM shall pay ACSB royalties with respect to the use of the applicable Subject IP on the terms set
forth in Section 2.02 below. 
 Section 2.02 Royalties. 
 (a) Payments in Respect of Net Sales. 
 (i) If BGM shall sell any products based on any Subject IP (each, a “Subject Product”), and such sale
would, absent the License granted hereunder with respect to such Subject IP, infringe one or more Valid Claims with respect to such Subject IP, BGM shall pay ACSB a royalty equal to such percentage (if any) of Net Sales of such Subject Product, and
upon such additional terms and conditions, as shall be set forth in the Licensing Addendum in which the applicable Subject IP is identified. If such Valid Claims relate to Subject IP identified in two or more Licensing Addenda, the royalty to be
paid to ACSB shall be determined using the average of the applicable percentages set forth in all such Licensing Addenda. 
 (ii) Limitations on Royalties on Net Sales. The payment of royalties with respect to Subject Products under this Agreement shall be subject to the following conditions: 
 1) Royalties on Net Sales of a particular Subject Product at the rates set forth above shall accrue as of the date of
First Commercial Sale of such Subject Product and shall continue and accrue until the expiration of the last to expire Valid Claim relating to such Subject Product. Thereafter, BGM shall be relieved of any royalty payment with respect to such
Subject Product. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 5 

 2) No royalties shall accrue on the disposition of reasonable
quantities of Subject Products by BGM, Affiliates or Sublicensees as samples (promotion or otherwise) or as donations (for example, to non-profit institutions or government agencies) or to clinical trials. 
 (b) Payments in the Event of Sublicense. In the event BGM enters into a Sublicense with a Third Party granting to the
Sublicensee a sublicense under any rights granted to BGM pursuant to a License of any Subject IP hereunder (the “Sublicensed Rights”), BGM’s obligation to pay royalties under Section 2.02(a) above with respect to
the Sublicensed Rights subject to the Sublicense shall terminate and, in lieu thereof, BGM shall pay to ACSB such percentage of all Sublicensing Income received by BGM from the Third Party Sublicensee with respect to the Sublicensed Rights subject
to the Sublicense, and upon such additional terms and conditions, as shall be set forth in the Licensing Addendum in which the applicable Subject IP is identified. subject. To the extent the Sublicensed Rights do not include all of the rights
granted to BGM with respect to the applicable Subject IP, ACSB shall continue to be entitled to royalties under Section 2.02(a) with respect to those rights retained by BGM or its Affiliates and not subject to the Sublicense. Amounts
payable to ACSB based on Sublicensing Income shall be payable for the same term as royalties would have been payable pursuant to Section 2.02(a)(ii)1) above. 
 (c) Affiliate Sales. In the event that BGM transfers Subject Products to one of its Affiliates, there shall be no royalty due at the time of transfer. Subsequent sales of Subject Products by
the Affiliate to end users (which are not Sublicensees) shall be reported as Net Sales hereunder by BGM. 
 (d) Compulsory Licenses. If a compulsory license is granted to a Third Party with respect to any Subject Product in any country with a royalty rate lower than the royalty rate provided by Section 2.02(a)(i), then the
royalty rate to be paid by BGM on Net Sales of such Subject Product in that country under Section 2.02(a)(i) shall be reduced to the rate paid by the compulsory Third Party licensee. 
 (e) Third Party Licenses. If one or more licenses from a Third Party or Third Parties are obtained by BGM with the prior or
subsequent approval of ACSB, which approval shall not be unreasonably withheld, in order to make, have made, use, sell or import any Subject Product, the royalties or other payments payable by BGM to ACSB under Section 2.02(a) or
Section 2.02(b) hereof, as applicable, shall be reduced by an amount equal to the aggregate royalty payments payable to such Third Party(ies) in connection with such Subject Product. 
 (f) Combination Product. Notwithstanding the provisions of Section 2.02(a), in the event a Subject Product is sold
as a combination product with other components, Net Sales, for purposes of royalty payments on the combination product, shall be calculated by multiplying the Net Sales of that combination product by the fraction A/B, where A is the gross selling
price of

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 6 

 
the Subject Product sold separately and B is the gross selling price of the combination product. If no such separate sales are made by BGM or its Affiliates, Net Sales for royalty determination
shall be calculated by multiplying Net Sales of the combination product by the fraction C/(C+D), where C (excluding the fully allocated cost of the other component in question) is the fully allocated cost of the component based on Subject IP and D
is the fully allocated cost of such other components. 
 (g) Report of Amounts Due. Within 60 days after the end of
each calendar half-year of BGM, BGM shall deliver to ACSB a statement of its calculation of Net Sales and Sublicensing Income derived from sales or licensing of Subject Products during such calendar half-year and any amounts due ACSB with respect
thereto, calculated as set forth in Section 2.02(a) (each such statement, a “Royalty Statement”). BGM shall preserve, and shall cause its Affiliates to preserve, all books and records relevant to the preparation of each
Royalty Statement for a period of at least five years after the delivery of such Royalty Statement to ACSB, and ACSB will be entitled to appoint an external auditor to verify whether the Royalty Statement is in accordance with such books and
records. On reasonable notice and during regular business hours, BGM will provide such auditor full access to all such books and records and will provide such assistance to enable such verification as such auditor may reasonably request. BGM shall
use commercially reasonable efforts to include audit and books and records preservation provisions similar to those set forth in this subsection in any Sublicenses that it shall grant. 
 (h) Timing and Method of Payment. BGM shall pay ACSB any amounts due with respect to a particular calendar half-year by wire
transfer to a bank account designated by ACSB within 30 days following delivery of the Royalty Statement for such year. To the extent any amounts due are to be offset against any prepayments of royalties that BGM shall have made, BGM shall, in lieu
of paying such amounts, send ACSB written notice of such offset. 
 (i) Payment Exchange Rate. All payments to ACSB
under this Agreement shall be made in Euros unless otherwise agreed by the Parties. In the case of sales outside the United States, the rate of exchange to be used in computing Net Sales and Sublicensing Income shall be calculated monthly in
accordance with GAAP and based on the conversion rates published in the Wall Street Journal, Eastern edition (if available). 
 (j) Tax Withholding. For so long as ACSB is domiciled in The Netherlands and BGM is domiciled in the United States of America, all sums payable under or by virtue of this Agreement and to be received by ACSB shall be free from
any deduction by any authority other than government authorities of The Netherlands in respect of taxes, import duties, or other charges and except for those withholding taxes (and other deductible taxes in The Netherlands) payable by law in The
Netherlands which ACSB (in accordance with the Double Tax Treaty between The Netherlands and the US) can recover from the Dutch Tax authorities, in which case BGM shall provide all necessary assistance and shall make available to ACSB the original
tax receipts thereof promptly upon payment. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 7 

 (k) Exchange Controls. Notwithstanding any other provision of this Agreement, if
at any time legal restrictions prevent the prompt remittance of part or all of the payments set forth in this ARTICLE II in any country, payment shall be made through such lawful means or methods as BGM may determine after consultation with
ACSB. When in any country the law or regulations prohibit both the transmittal and deposit of royalties on sales in such a country, royalty payments shall be suspended for as long as such prohibition is in effect (and such suspended payments shall
not accrue interest), and, promptly after such prohibition ceases to be in effect, all royalties or other payments that BGM would have been obligated to transmit or deposit, but for the prohibition, shall be deposited or transmitted, as the case may
be, to the extent allowable (with any interest earned on such suspended royalties which were placed in an interest-bearing bank account in that country, less any transactional costs). If the royalty rates specified in this Agreement should exceed
the permissible rate established in any country, the royalty rate for sales in such country shall be adjusted to the highest legally permissible or government-approved rate. 
 Section 2.03 Development Activities. Each Licensing Addendum may provide for the Parties to undertake activities
relating to the development and commercialization of the Subject IP identified in such Licensing Addendum on the terms set forth therein. 
 Section 2.04 Termination of License on Discontinuance of Product. If BGM shall, at any time after the First Commercial Sale of a Subject Product, discontinue the production and
sale of such Subject Product and of any other Subject Products that are based upon the same Subject IP as such Subject Product, then any License granted by ACSB to such Subject IP shall terminate and BGM shall provide ACSB with access to all
biological and clinical data in BGM’s possession that were generated from such Subject IP. 
 ARTICLE III 
 INTELLECTUAL PROPERTY RIGHTS AND PROTECTION 
 Section 3.01 Ownership of Subject IP. Intellectual Property Rights belonging to ACSB at the time a Licensing Addendum is executed with respect thereto shall remain the property of
ACSB. Ownership of Intellectual Property Rights developed jointly by the Parties pursuant to activities undertaken pursuant to this Agreement shall be determined in accordance with inventorship as determined by United States patent law as if the
subject inventions had been wholly made within the United States; provided, however, that any such Intellectual Property Rights belonging to ACSB shall be Subject IP and therefore subject to a License on the terms and conditions of this
Agreement and the applicable Licensing Addendum. Nothing in this Agreement is intended to grant ACSB ownership or any other rights with respect to any Intellectual Property Rights now or hereafter owned by BGM. 
 Section 3.02 Patent Prosecution. Unless otherwise provided in the applicable Licensing Addendum, ACSB shall prepare,
file, prosecute and maintain all patents and patent applications covering any invention related to Subject IP, pursuant to such strategies and using such patent counsel as ACSB and BGM shall mutually agree. The Parties shall collaborate and
cooperate in good faith regarding all such matters, and ACSB shall not make any filing or take any other material action related thereto without the prior approval of BGM. BGM shall reimburse ACSB for all reasonable and customary third-party costs
of such patent preparation, filing, prosecution and maintenance upon receipt of appropriate supporting documentation. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 8 

 Section 3.03 Infringement of Subject IP by Third Parties.

 (a) Each Party shall promptly give the other Party notice of any actual or threatened infringement of any Subject IP by
any Third Party that comes to such Party’s attention. The Parties will thereafter consult and cooperate fully to determine a course of action, including, without limitation, the commencement of legal action by any Party against any such Third
Party. However, BGM shall have the first right to initiate and prosecute such legal action at its own expense and in the name of BGM and ACSB. BGM shall promptly inform ACSB if BGM elects not to exercise such first right, and ACSB thereafter shall
have the right either to initiate and prosecute such action in the name of ACSB and, if necessary, BGM. In no event shall BGM be obligated to enforce or defend any of the Subject IP. Neither Party shall enter into any settlement or compromise of any
claim relating to the Subject IP without the consent of the other Party, which consent shall not be unreasonably withheld. BGM makes no representation or warranty that it will be able to obtain satisfactory results from any such legal action and BGM
shall have no liability hereunder with respect to any legal action pursued or not pursued. 
 (b) The costs of any legal
action described in Section 3.03(a) shall be borne by the Party that initiates such action (and subject to recovery by such Party as provided in Section 3.03(d) below). 
 (c) For any such legal action or defense, in the event that any Party is unable to initiate, prosecute, or defend such action solely in
its own name, the other Party will join such action voluntarily and will execute all documents necessary for the Party to prosecute, defend and maintain such action. In connection with any such action, the Parties will cooperate fully and will
provide each other with any information or assistance that either reasonably may request. 
 (d) Any recovery obtained by
either Party shall be shared as follows: 
 (i) the Party that initiated and prosecuted, or maintained the
defense of, the action shall recoup all of the costs and expenses (including reasonable attorneys’ fees) incurred by such Party in connection with the action, whether the recovery is by settlement or otherwise; 
 (ii) the other Party then shall, to the extent possible, recover all of the costs and expenses (including reasonable
attorneys’ fees) incurred by such Party in connection with the action; and 
 (iii) any remaining
amount shall be deemed to be revenues from the sale of Subject Products based on the Subject IP to which such recovery relates, and royalties shall be payable on any Net Sales Profits that result from such deemed revenues according to the
percentages (if any) provided in the Licensing Addendum in which such Subject IP is identified. If such Subject IP is identified in two or more Licensing Addenda, the royalty to be paid shall be equal to the average of the applicable percentages set
forth in all such Licensing Addenda. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 9 

 Section 3.04 Indemnification by BGM. 
 (a) BGM shall indemnify, defend and hold ACSB, the University, CARIM and BioMedbooster and each of their respective directors,
officers, employees and agents (each, an “Indemnified Party”) harmless from and against all claims or suits by Third Parties arising out of (i) the alleged infringement of Intellectual Property Rights owned by a Third Party
resulting from any use by BGM or its Affiliates of any Subject IP or (ii) the development, manufacture, use, handling, storage, sale or other disposition by BGM or its Affiliates of any Subject Products; provided, however, that
BGM’s obligation to indemnify under this Section 3.04 shall not apply to any claim arising out of the gross negligence or willful misconduct of an Indemnified Party. 
 (b) ASCB shall give prompt written notice to BGM of any suits, claims or demands which may give rise to any matter for which
indemnification may be required under this Section 3.04; provided, however, that failure to give such notice shall not relieve BGM of its obligation to provide indemnification hereunder except, if and to the extent that such
failure materially affects the ability of BGM to defend the applicable suit, claim or demand. BGM shall be entitled to assume the defense and control of any such suit, claim or demand at its own cost and expense. In the event that BGM declines to or
fails to timely assume control of any such suit, claim or demand, the Indemnified Party or Indemnified Parties entitled to indemnification shall be entitled to assume such control, conduct the defense of, and settle such suit, claim or action, all
at the sole cost and expense of BGM. Neither BGM nor any Indemnified Party shall settle or dispose of any such matter in any manner which would adversely affect the rights or interests of the other party without the prior written consent of such
other party, which shall not be unreasonably withheld or delayed. BGM and each Indemnified Party shall cooperate with each other and their respective counsel in the course of the defense of any such suit, claim or demand, such cooperation to include
without limitation using reasonable efforts to provide or make available documents, information and witnesses. 
 Section 3.05 Regulatory Matters. BGM shall own, control and retain primary legal responsibility for the preparation, filing and prosecution of all filings and regulatory applications required to obtain authorization
to commercially develop, sell and use any Subject Products. Upon BGM’s request, ACSB shall consult and cooperate with BGM in connection with any such matters, and BGM shall reimburse ACSB for any out of pocket expenses reasonably incurred by
ACSB in connection with such consultation and cooperation. 
 Section 3.06 Agreement Not to Challenge;
Further Assurances. ACSB shall not challenge, in any court or proceeding, or assist any Third Party in challenging, the validity of any Subject IP or BGM’s ownership of and/or rights therein. ACSB shall further sign such additional and
further documents, and take such other actions, as may be reasonably requested by BGM to create, perfect, confirm and enforce BGM’s rights in Subject IP. 
 Section 3.07 Data, Publications and Reports. ACSB shall, as and to the extent requested by BGM, provide BGM with copies of all biological and clinical data, publications, reports
and other information in ACSB’s possession relating to any Subject IP in order to support BGM’s efforts to develop, register and commercialize such Subject IP and otherwise in connection with the exercise of BGM’s rights under this
Agreement. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 10 

 ARTICLE IV 
 RIGHTS WITH RESPECT TO NEW PROJECTS AND DISCOVERIES 
 Section 4.01 First Look Right of ACSB. Before seeking, negotiating or soliciting offers from Third Parties to act as investigators or collaborators in any Subject BGM Project, BGM shall give written notice of such
Subject BGM Project to ACSB (a “BGM Project Notice”), and shall provide ACSB with such additional information regarding such Subject BGM Project as ACSB shall reasonably request for the purpose of evaluating its interest therein
within five (5) days following delivery of such BGM Project Notice. No later than ten (10) days following receipt of the applicable BGM Project Notice or, if later, five (5) days following receipt of any additional information
requested by ACSB in response to such BGM Project Notice as described above, ACSB may give written notice to BGM that it wishes to negotiate a role for itself, CARIM or the University as an investigator or collaborator in connection with such
Subject BGM Project (a “First Look Right”) on terms that are consistent with the terms of this Agreement. If ACSB so exercises its First Look Right with respect to a Subject BGM Project, the Parties shall negotiate exclusively (but
solely as to such role as BGM reasonably anticipates may be filled by ACSB, CARIM and/or the University) and in good faith, for a period of up to thirty (30) days after such exercise, the terms of an agreement (which may take the form of a
Licensing Addendum) pursuant to which ACSB, CARIM and/or the University shall provide project or collaboration services for such Subject BGM Project; provided, that no Party shall have any obligation to enter into any such agreement. If, with
respect to a particular Subject BGM Project, ACSM does not so exercise its First Look Right or such an agreement is not entered into within such 30-day period, then BGM shall be free to approach Third Parties with respect to, and otherwise to
conduct, such Subject BGM Project without further obligation to ACSB. 
 Section 4.02 Right of First Offer
of BGM. 
 (a) If ACSB shall discover or acquire rights to any new Markers (“Subject Markers”), ACSB
shall grant BGM a right to negotiate a Licensing Addendum identifying such Markers as Subject IP (a “Right of First Offer”) on the terms set forth herein. 
 (b) Before seeking, negotiating or soliciting offers from Third Parties for any agreement or other arrangement under which any Third
Party would acquire any rights with respect to any Subject Markers, ACSB shall give written notice of such Subject Markers to BGM (an “ACSB Marker Notice”), and shall provide BGM with such additional information regarding such
Subject Markers as BGM shall reasonably request for the purpose of evaluating its interest therein within five (5) days following delivery of such ACSB Marker Notice. BGM may exercise its Right of First Offer with respect to such Subject
Markers by giving written notice of exercise to ACSB no later than ten (10) days following receipt of the applicable ACSB Marker Notice or, if later, five (5) days following receipt of any additional information requested by BGM in
response to such ACSB Marker Notice as described above. If BGM so exercises its Right of First Offer with respect to any Subject Markers, the Parties shall negotiate exclusively and in good faith, for a period of up to thirty (30) days after
such exercise, the terms of a Licensing Addendum that identifies such Subject Markers as Subject IP; provided, that no Party shall have any obligation to enter into any such Licensing Addendum. If, with respect to any

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 11 

 
particular Subject Markers, BGM does not so exercise its Right of First Offer or such a Licensing Addendum is not entered into within such 30-day period, then ACSB shall be free to approach Third
Parties with respect to such Subject Markers. 
 Section 4.03 No Additional Restrictions. Nothing in
this Agreement is intended to preclude either Party from pursuing business activities outside the scope of this Agreement. Without limiting the generality of the foregoing, and subject to compliance with the express terms of this Agreement, nothing
in this Agreement is intended to preclude ACSB from entering into agreements for the discovery, validation, development and commercialization of novel biomarkers with biopharmaceutical or diagnostic companies, or to preclude ACSB from
commercializing any Intellectual Property Rights, in either case outside the scope of this Agreement. 
 ARTICLE V 
 REPRESENTATIONS AND WARRANTIES/LIABILITIES AND INDEMNIFICATION 
 Section 5.01 Representations and Warranties of BGM. BGM represents and warrants to ACSB as follows: 
 (a) Organization and Authority. BGM is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. BGM has the requisite corporate power and
authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery by BGM of this Agreement and the performance by BGM of its obligations hereunder
have been duly and validly authorized and BGM has taken all necessary corporate action with respect thereto. This Agreement has been duly and validly executed and delivered by BGM and constitutes the legal, valid and binding obligation of BGM,
enforceable against it in accordance with its terms, except as such enforcement may be limited or affected by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and by
general principles of equity (regardless of whether enforceability is considered in a proceeding in equity or at law) 
 (b) No Conflict. Neither the execution, delivery or performance by BGM of this Agreement nor the consummation by BGM of the transactions contemplated hereby will (i) conflict with or result in a breach of any provision of
the constitutive documents of BGM or any agreement to which BGM is a party or (ii) violate any provision of law, or any order, writ, injunction, permit, judgment or decree of any court or other governmental authority to which BGM is subject or
by which its assets are bound. 
 (c) Rights to Intellectual Property. BGM has all necessary rights and authority to
grant the licenses and other rights in respect of Intellectual Property set forth in this Agreement without the need to make any payment to, obtain any consent from or take any other action with respect to any Third Party. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 12 

 Section 5.02 Representations and Warranties of ACSB. ACSB represents
and warrants to BGM as follows: 
 (a) Organization and Authority. ACSB will be a corporation duly organized,
validly existing and in good standing under the laws of The Netherlands. ACSB has the requisite corporate power and corporate authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the transactions
contemplated hereby. The execution and delivery by ACSB of this Agreement and the performance by ACSB of its obligations hereunder have been duly and validly authorized and ACSB has taken all necessary corporate action with respect thereto. This
Agreement has been duly and validly executed and delivered by ACSB and constitutes the legal, valid and binding obligation of ACSB, enforceable against it in accordance with its terms, except as such enforcement may be limited or affected by
applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and by general principles of equity (regardless of whether enforceability is considered in a proceeding in equity or at
law). 
 (b) No Conflict. Neither the execution, delivery or performance by ACSB of this Agreement nor the
consummation by ACSB of the transactions contemplated hereby will (i) conflict with or result in a breach of any provision of the constitutive documents of ACSB or any agreement to which ACSB is a party or (ii) violate any provision of
law, or any order, writ, injunction, permit, judgment or decree of any court or other governmental authority to which ACSB is subject or by which its assets are bound. 
 (c) Rights to Intellectual Property. ACSB, together with the University and BioMedbooster, has all necessary rights and authority to grant the licenses and other rights in respect of
Intellectual Property set forth in this Agreement without the need to make any payment to, obtain any consent from or take any other action with respect to any Third Party. 
 Section 5.03 NO ADDITIONAL WARRANTIES. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE V AND
ANY REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN A LICENSING ADDENDUM, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND TO THE OTHER PARTY, AND EACH PARTY EXPRESSLY
DISCLAIMS ALL OTHER WARRANTIES, WHETHER EXPRESS OR IMPLIED AND WHETHER ARISING BY STATUTE, OPERATION OF LAW, COURSE OF DEALING OR OTHERWISE. 
 Section 5.04 Limitation of Liability. Under no circumstance shall either Party be liable to the other Party for any indirect or consequential damages or losses (including, but not
limited to, damages for loss of profit) related to the development and exploitation of the Subject IP. 
 ARTICLE VI 

CONFIDENTIALITY 
 Section 6.01 Access to Confidential Information. Each Party acknowledges that in connection with the transactions and activities contemplated by this Agreement it may receive or be exposed to Confidential Information
of the other Party. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 13 

 Section 6.02 Obligation to Keep Confidential. Save as expressly
provided otherwise in this Agreement, each Party shall not disclose the Confidential Information of the other Party to any Third Party and shall keep such Confidential Information strictly confidential by employing procedures for safeguarding
Confidential Information at least as rigorous as such Party employs for its own Confidential Information, and in no event less than reasonable procedures. Notwithstanding the foregoing, each Party shall be entitled to disclose the existence and
contents of this Agreement to (i) such Party’s employees, accountants, financial advisors, outside counsel and other representatives with a bona fide need to know (collectively, “Representatives”), and (ii) venture
capital funds, banks and other Persons from whom such Party believes it has a reasonable likelihood of obtaining debt or equity financing (“Investors”); provided that, prior to making any such disclosure, such Party shall
inform such Representative or Investor of the requirements of this Agreement and obtain from such Representative or Investor his or her agreement to be bound thereby. 
 Section 6.03 Exceptions. The confidentiality obligations under this Agreement shall not apply to Confidential Information that the receiving Party can demonstrate by means of dated
documentation: (a) was already in the public domain at the time it was disclosed or subsequently enters the public domain through no fault of the receiving Party; (b) was known to the receiving Party or in its possession, as evidenced by
dated documentation prior to receipt of such Confidential Information, (c) was developed by the receiving Party independently and without use of Confidential Information provided by the disclosing Party under this Agreement and without any
breach of this Agreement or (d) was lawfully received by the receiving Party on a non-confidential basis from a Third Party who was not bound by a similar obligation of confidentiality in relation to the Confidential Information. 
 Section 6.04 Required Disclosure. In the event that, in connection with any legal proceeding or investigation by a
competent court or governmental or administrative authority, either Party (or any of its representatives) is required (by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar
process) to disclose any Confidential Information received under this Agreement, such Party shall provide the other Party with prompt notice of such request(s) so that the other Party may seek an appropriate protective order or other appropriate
remedy. In the event that such protective order or other remedy is not obtained promptly or in the event that the other Party grants a waiver hereunder, the Party concerned may furnish that portion (and only that portion) of the Confidential
Information which, in the written opinion of that Party’s legal counsel, the Party concerned is legally compelled to disclose and will exercise its best efforts to obtain an order or other adequate assurance that such Confidential Information
will be treated confidentially. Notwithstanding the foregoing, the Party may disclose that portion (and only that portion) of the Confidential Information, which, in the written opinion of its legal counsel, the Party is legally required to disclose
in order to comply with applicable law. 
 Section 6.05 Confidentiality of Agreement; Breach. The
Parties acknowledge the confidential nature of this Agreement and neither Party shall disclose the contents of this Agreement without obtaining the prior approval of the other Party in writing, save as required by applicable law or by either Party
in connection with the enforcement of its rights hereunder. Any breach by either Party of any of its confidentiality obligations under this ARTICLE VI shall not affect any right or remedy to which the non-breaching Party would be entitled at law
absent this Agreement. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 14 

 ARTICLE VII 
 PUBLICATIONS 
 Section 7.01 Authorship. Authorship and
other matters relating to publications arising from activities conducted under this Agreement shall be as set forth in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals of the International Committee of Major Journal Editors
(http://www.icmje.org/). 
 Section 7.02 Advance Notice of Publication. Notwithstanding any other
provision of this Agreement to the contrary, ACSB shall, prior to submission for publication of any manuscript, poster, presentation, abstract or other written or oral material describing any activities related to this Agreement, provide BGM thirty
(30) days to review any such manuscript and fifteen (15) days to review any such poster, presentation, abstract or other written or oral material for the purpose of determining if any patentable information is disclosed thereby. If BGM
requests in writing, ACSB shall withhold any publication or presentation an additional sixty (60) days solely to permit BGM to seek patent protection and to remove any confidential or proprietary information from all publications. 

ARTICLE VIII 
 TERM AND TERMINATION 
 Section 8.01 Term. This Agreement shall be effective as of the
Effective Date, shall remain in effect through the period ending on the date five years after the Effective Date (the “Initial Term”), and shall automatically renew for subsequent one-year periods thereafter (each, a
“Renewal Term”), unless either Party shall give written notice of its intention not to renew no later than 30 days before the end of the Initial Term or Renewal Term then in effect. 
 Section 8.02 Termination for Cause. Each Party may terminate this Agreement at any time by means of a written notice
to the other Party in the event that the other Party fails to perform any material obligation under this Agreement and such failure (if susceptible to remedy) is not remedied within 30 days after receipt of a notice specifying the nature of such
failure and requiring it to be remedied (any such termination, a “Termination for Cause”). Such right of termination shall not be exclusive of any other remedy or means of redress to which the non-defaulting Party may be lawfully
entitled and all such remedies shall be cumulative. 
 Section 8.03 Bankruptcy Etc. Each Party may
terminate this Agreement with immediate effect by means of a written notice to the other Party in the event that: (a) a creditor or other claimant takes possession of, or a receiver, administrator or similar officer is appointed over any of the
assets of the other Party or (b) the other Party makes any voluntary arrangement with its creditors or becomes subject to any court or administration order pursuant to any bankruptcy or insolvency law. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 15 

 Section 8.04 Effect of Termination. The obligations of the Parties
under this Agreement and any Licensing Addenda that either expressly or by their nature would continue beyond the expiration or termination of this Agreement, (including, without limitation, those concerning payment of a portion of revenues,
confidentiality, warranty and liability as well as obligations to grant licenses) shall survive expiration or earlier termination of this Agreement. Without limiting the generality of the foregoing, any licenses to Subject IP and the rights and the
obligations of the Parties under ARTICLE II, ARTICLE III, ARTICLE V, ARTICLE VI, ARTICLE VII, ARTICLE VIII and ARTICLE IX, and any similar provisions in any Licensing Addenda, shall survive expiration
or earlier termination of this Agreement; provided, however, that any exclusive licenses granted to BGM hereunder shall become non-exclusive if ACSB shall effect a Termination for Cause. 
 ARTICLE IX 
 MISCELLANEOUS 
 Section 9.01 Assignment; Binding Effect. Neither this Agreement nor any rights
granted hereunder may be assigned by either Party without the other Party’s prior written consent, except that (a) either Party may assign this Agreement in its entirety to any of its Affiliates or to a purchaser of all or substantially
all of its assets or business to which this Agreement principally relates (whether such transaction is effected by a sale of stock, equity or assets or by merger or other transaction), and (b) ACSB shall be entitled to assign this Agreement or
any rights granted hereunder to BioMedbooster or the University, to which assignment BGM hereby consents in advance. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and permitted assigns. 
 Section 9.02 No Third Party Beneficiaries. Except for the
provisions of Section 3.04 as they relate to the Indemnified Parties and the license grant to the University, BioMedbooster and their respective Affiliates set forth in Section 2.01(a), nothing herein expressed or implied is
intended to confer upon any Person, other than the parties hereto and their respective permitted successors and assigns, any rights, obligations or liabilities under or by reason of this Agreement. 
 Section 9.03 No Waiver by Conduct; Waiver. The failure of either Party to enforce at any time any provision of this
Agreement shall not be construed as a waiver of such provision or of the right of such party thereafter to enforce such provision. Any provision of this Agreement may be waived only by a written instrument signed by both of the parties hereto.

 Section 9.04 Governing Law/Jurisdiction. This Agreement shall be governed and construed in accordance
with the laws of The Netherlands, without regard to any conflicts of law principles thereof. In the event of a dispute regarding the construction or interpretation of this Agreement the Parties agree that such dispute shall be exclusively settled by
the court competent for the municipality of Maastricht, The Netherlands; provided, however that ACSB shall have the right to submit any such dispute to the court competent for the jurisdiction in which BGM is then located. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 16 

 Section 9.05 Severability. If any provision of this Agreement or the
application thereof to any Person, or to any event or circumstance, is held invalid or unenforceable to any extent, the remainder of this Agreement and the application of that provision shall be enforced to the fullest extent permitted by law.

 Section 9.06 Counterparts. This Agreement may be executed in counterparts with the same effect as if
the Parties had signed the same document, and such counterparts, when taken together, shall be construed as and shall constitute one and the same instrument. 
 Section 9.07 Entire Agreement; Amendment. This Agreement, together with the Licensing Addenda executed hereunder, constitutes the entire agreement between the Parties regarding the
subject matter hereof, and shall not be amended, altered or changed except by a written agreement signed by the Parties. 
 Section 9.08 Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt
or: (a) personal delivery to the Party to be notified, (b) sending by confirmed facsimile if sent and confirmed during normal business hours of the recipient, or, if sent and confirmed during other than normal business hours of the
recipient, then on the next business day after such sending and confirmation or (c) delivery by an internationally recognized courier during normal business hours of the recipient, or, if so delivered during other than normal business hours of
the recipient, on the next business day after such delivery. All communications shall be sent to the respective parties at their facsimile number or address as set forth below, or to such facsimile number or address as subsequently modified by
written notice given in accordance with this Section 9.08: 
  

			
	 BG Medicine, Inc.
	  	ACS Biomarker B.V.
	 610 N. Lincoln Street
	  	Oxfordlaan 70
	 Waltham, MA 02451
	  	6229 EV Maastricht
	 ATTN: President
	  	ATTN.:
	 facsimile: +1 (781) 895-1119
	  	facsimile:

 REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 17 

 IN WITNESS WHEREOF, the Parties have executed this Product License and Collaboration
Agreement as an instrument under seal as of the date first above written. 
  

									
	BG MEDICINE, INC.	 		 	ACS BIOMARKER B.V., i.o.
			
		 		 	By its incorporators as listed below:
					
	By:	 	 /s/ Pieter Muntendam
	 		 		 	
		 	Its President and CEO	 		 		 	
			
	THE UNIVERSITY OF MAASTRICHT	 		 	THE UNIVERSITY OF MAASTRICHT
	(solely for purposes of Section 3.04)	 		 	
					
	By:	 	 /s/ Jo Ritzen
	 		 	By:	 	 /s/ Jo Ritzen

		 	Its President	 		 		 	Its President
			
	BIOMEDBOOSTER, B.V. (solely for purposes of Section 3.04)	 		 	BIOMEDBOOSTER, B.V.
					
	By:	 	 /s/ Tom Melvis
	 		 	By:	 	 /s/ Tom Melvis

		 	Its Attorney	 		 		 	Its Attorney
				
		 		 		 	 /s/ Yigal Pinto

		 		 		 	Yigal Pinto
		 		 	
				
		 		 		 	 /s/ Mat Daemen
 Mat Daemen

		 		 		 
		 		 	
				
		 		 		 	 /s/ Tilman Hackeng
 Tilman Hackeng

		 		 		 
		 		 	
				
		 		 		 	 /s/ Marcel Kannekens
 Marcel Kannekens

		 		 		 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 18 

 Exhibit A 
 Licensing Addendum No. 1 
 This Licensing Addendum No.
1 is entered into under and pursuant to the terms of the Product License and Collaboration Agreement dated as of May     , 2007 by and between BG Medicine, Inc., a Delaware corporation, and ACS Biomarker B.V., a
corporation organized under the laws of The Netherlands (the “Product License Agreement”). In the event of any conflict between the Product License Agreement and the express terms of this Licensing Addendum, the terms of this
Licensing Addendum shall prevail. Capitalized terms used but not defined in this Licensing Addendum shall have the meanings assigned to them in the Product License Agreement. 
  

	1.	Subject IP. The following Intellectual Property Rights shall constitute Subject IP and therefore be licensed to BGM on the terms set forth in the Product License
Agreement: 

  

	2.	Exclusivity. 

  

	3.	Field of Use. 

  

	4.	Term. 

  

	5.	Territory. 

  

	6.	Sublicensing. 

  

	7.	Field of Interest: The Field of Interest is hereby expanded to include: 

  

	8.	Activities, Rights and Obligations. The Parties shall undertake the activities, and have the rights and obligations, as follows: 

  

	9.	Royalties. The following royalties shall be payable by BGM to ACSB, in each case on the terms set forth in the Product License Agreement:

  

	10.	Additional Representations and Warranties. The Parties make the following representations and warranties in addition to those set forth in the Product License
Agreement: 

  

	11.	Additional Terms. The following additional terms shall apply: 

 IN WITNESS WHEREOF, the Parties have executed this Licensing Addendum No.      effective as of this      day of
        ,         . 
  

									
	BG MEDICINE, INC.	 		 	ACS BIOMARKER B.V.
					
	By:	 	 	 		 	By:	 	 
		 	Its	 		 		 	Its

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Licensing Addendum No. 1 
 This Licensing Addendum No. 1 is entered into under and pursuant to the terms of the Product License and Collaboration Agreement dated
as of May 4, 2007 by and between BG Medicine, Inc., a Delaware corporation, ACS Biomarker B.V. i.o., a corporation organized under the laws of The Netherlands to be established by the University of Maastricht (the “University”),
BioMedbooster B.V., a corporation organized under the laws of The Netherlands (“BioMedbooster”), ACS Holding B.V., a corporation organized under the laws of the Netherlands to be established by Y. Pinto Holding B.V. i.o. to be established
by Yigal Pinto, M. Daemen Holding B.V. i.o. to be established by Mat Daemen, Tilman Hackeng Holding B.V. i.o. to be established by Tilman Hackeng, and Marcel Kannekens and the other parties thereto (the “Product License
Agreement”). In the event of any conflict between the Product License Agreement and the express terms of this Licensing Addendum, the terms of this Licensing Addendum shall prevail. Capitalized terms used but not defined in this Licensing
Addendum shall have the meanings assigned to them in the Product License Agreement. 
  

	1.	Subject IP. The following Intellectual Property Rights shall constitute Subject IP and therefore be licensed to BGM on the terms set forth in the Product License
Agreement and in this Licensing Addendum: 

  

	 	a.	all rights of any nature in and to patent application no. EP 030078161 with a priority date of 9 October 2003, entitled “Method for identifying a subject at
risk of developing heart failure by determining the level of Galactin-3 or Thrombospondin-2,” and all related patents and patent applications (including, but not limited to, international application PCT/EP2004/010879 (pub. no. W02005/04081)
and any and all other foreign applications, divisional applications, continuations, continuations in part, revisions, re-examinations and reissues anywhere in the world) that in full or in part can claim priority of said patent application
(“ACSB Pre-Existing IP”). To the extent ACSB does not possess the right to grant the License described in this Licensing Addendum as of the date hereof, such License shall become effective, and shall be deemed granted by ACSB,
immediately upon ACSB’s acquisition of such right. 

  

	 	b.	all rights of ACSB in any Intellectual Property developed by either Party under the Implementation Plan (as defined below), including without limitation (i) all
clinical, drug discovery, research, investigatory, or other methods, uses or applications and (ii) all Intellectual Property Rights throughout the world in any of the foregoing, including without limitation patents, the right to apply for
patents and trade secret or equivalent rights (“Jointly Developed IP”). 

 For the avoidance of
doubt, all rights of BGM in any Jointly Developed IP shall remain the sole and exclusive property of BGM, and ACSB shall not have any license or other rights thereto. 
  

	2.	 Exclusivity. The License granted under this Licensing Addendum shall be exclusive, even as to ACSB; provided, however, that in the event
BGM breaches any material term of the Implementation Plan, which breach is not cured within 30 days following written

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	 
notice thereof by ACSB to BGM, such License shall become non-exclusive and provided further, that ACSB, BioMedbooster, the University and their respective Affiliates shall have the limited
license to the ACSB Pre-Existing IP and Jointly Developed IP set forth in Section 2.01(a) of the Product License Agreement. 

  

	3.	Field of Use. The License granted under this Licensing Addendum shall permit BGM to use and exploit the ACSB Pre-Existing IP and Jointly Developed IP for any
purpose whatsoever. 

  

	4.	Term. The License granted under this Licensing Addendum shall be perpetual. 

  

	5.	Sublicensing. The License granted under this Licensing Addendum shall include the right to grant sublicenses to any of the rights of BGM.

  

	6.	Territory. The License granted under this Licensing Addendum shall be valid worldwide. 

  

	7.	Field of Interest: The Field of Interest shall include the field of congestive heart failure. 

  

	8.	Activities, Rights and Obligations. The Parties shall undertake the activities, and have the rights and obligations, as follows: 

  

	 	a.	BGM and ACSB shall collaborate in good faith to develop a roadmap and implementation plan for development and commercialization of the ACSB Pre-Existing IP (the
“Implementation Plan”), and further agree that: 

  

	 	i.	BGM shall use commercially reasonable efforts to realize commencement of commercial distribution of Subject Products based on ACSB Pre-Existing IP to the extent
provided in the Implementation Plan, and shall inform ACSB at least once every calendar quarter about progress under the Implementation Plan. 

  

	 	ii.	ACSB shall provide such assistance in regard to the ACSB Pre-Existing IP and the activities described in the Implementation Plan as BGM shall reasonably request;
provided, however, that ACSB shall not be obligated to provide more than [***] man hours of such assistance in any twelve-month period unless BGM shall agree to compensate ACSB therefor at a reasonable commercial rate to be negotiated in good
faith by the Parties. 

  

	 	iii.	BGM shall reimburse ACSB for any out of pocket expenses reasonably incurred by ACSB in connection with the provision of such assistance. 

  

	 	b.	The Parties shall establish a scientific advisory board to provide input and guidance with respect to activities under the Implementation Plan.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 2 

	9.	Royalties. The following royalties shall be payable by BGM to ACSB, in each case on the terms set forth in the Product License Agreement:

  

	 	a.	a royalty equal to [***]% of Net Sales from Subject Products in the Field of Interest described in paragraph 7 of this Licensing Addendum that are developed solely
using ACSB Pre-Existing IP. 

  

	 	b.	a royalty equal to [***]% of Net Sales from Subject Products within the Field of Interest described in paragraph 7 of this Licensing Addendum that are developed using
any Jointly Developed IP (including without limitation Subject Products developed using Jointly Developed IP and ACSB Pre-Existing IP). 

  

	 	c.	a royalty equal to [***]% of Sublicensing Income from Subject Products in the Field of Interest described in paragraph 7 of this Licensing Addendum that are developed
solely using ACSB Pre-Existing IP. 

  

	 	d.	a royalty equal to [***]% of Sublicensing Income from Subject Products within the Field of Interest described in paragraph 7 of this Licensing Addendum that are
developed using any Jointly Developed IP (including without limitation Subject Products developed using Jointly Developed IP and ACSB Pre-Existing IP). 

  

	10.	Milestone Payments. BGM will make the following milestone payments to ACSB: 

  

	 	a.	$[***] payable within [***] days of the later to occur of (i) formation of ACSB and (ii) the transfer or exclusive license of rights to ACSB by the
University, BioMedbooster and any other applicable Third Parties described in paragraph 13.a. below. BGM’s obligation to make such payment shall be conditioned upon the delivery to BGM of (A) documentation of such formation and transfer or
licensing in form and substance reasonably satisfactory to BGM and (B) a document in form and substance reasonably satisfactory to BGM and signed by ACSB ratifying the Product License Agreement, this Licensing Addendum and any other Licensing
Addenda then existing and acknowledging its obligations and status as a party hereunder and thereunder. 

  

	 	b.	$[***] payable within [***] days after the first of the following events to occur: 

  

	 	i.	the acquisition by BGM of sufficient aliquots of plasma samples and data from the PRIDE study conducted at the Massachusetts General Hospital, Boston, MA and published
in Am J Cardiol 2005;95:948-954, with authorization for use and of sufficient quality for use as a pivotal regulatory study in conjunction with additional BGM studies, or 

  

	 	ii.	the initiation by BGM using ACSB Pre-Existing IP or Jointly Developed IP of full development of thrombospondin-2, with “full development” meaning the start of
assay development and a clinical qualification study of thrombospondin in congestive heart failure as required for US regulatory submission. 

  

	11.	 Royalty Prepayment. BGM will make the royalty prepayment to ACSB described below. Such prepayment shall be credited against any royalties
otherwise payable under this

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 3 

	 	 
Licensing Addendum or any other Licensing Addendum, but ACSB shall not be required to refund such prepayment. In the event that BGM pays royalties to ACSB under this or under any other Licensing
Addendum, the amount of prepayment shall be reduced by the amount of royalties so paid. 

  

	 	a.	$250,000 upon the occurrence of the first of the following events: 

  

	 	i.	Regulatory Approval for the US of a Subject Product within the Field of Interest described in paragraph 7 of this Licensing Addendum that has been developed using any
Jointly Developed IP or ACSB Pre-Existing IP; or 

  

	 	ii.	The issuance of a US or EU patent covering a Subject Product within the Field of Interest described in paragraph 7 of this Licensing Addendum that has been developed
using any Jointly Developed IP or ACSB Pre-Existing IP. 

  

	12.	Additional Representations and Warranties. The Parties make the following representations and warranties in addition to those set forth in the Product License
Agreement: 

  

	 	a.	ACSB represents and warrants to BGM that, upon the transfer or exclusive license to ACSB of rights by the University, BioMedbooster and any other applicable Third
Parties described in paragraph 13.a. below, it will be the exclusive owner or exclusive licensee of all right, title and interest in the ACSB Pre-Existing IP, with full right, power and authority to grant the License granted to BGM under this
Licensing Addendum. 

  

	13.	Additional Terms. The following additional terms shall apply: 

  

	 	a.	ACSB shall use its best efforts to cause all Intellectual Property Rights of the University, BioMedbooster and any other Third Parties in the ACSB Pre-Existing IP to be
transferred or exclusively licensed to ACSB as soon as possible after the execution of this Licensing Addendum. 

  

	 	b.	BGM shall reimburse patent prosecution costs previously incurred by ACSB in connection with the ACSB Pre-Existing IP upon presentation to BGM of appropriate
documentation, up to a maximum of $[***]. 

  

	 	c.	Each Party shall give the other Party prompt notice of the development of any Jointly Developed IP. 

 REMAINDER OF PAGE INTENTIONALLY LEFT BLANK 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 4 

 IN WITNESS WHEREOF, the Parties have executed this Licensing Addendum
No. 1 effective as of this 4th day of May, 2007.

  

							
	BG MEDICINE, INC.	 	 ACS BIOMARKER B.V., i.o.

			
		 		 	By its incorporators as listed below:
			
	By:	 	 /s/ Pieter Muntendam
	 	(i) THE UNIVERSITY OF MAASTRICHT
		 	Its President and CEO	 		 	
				
		 		 	By:	 	 /s/ Jo Ritzen

		 		 		 	Its President
			
		 		 	(ii) BIOMEDBOOSTER B.V.
				
		 		 	By:	 	 /s/ Tom Melvis

		 		 		 	Its Attorney
			
		 		 	(iii) ACS HOLDING B.V. i.o.
			
		 		 	By its incorporators as listed below:
			
		 		 	Y. PINTO HOLDING B.V. i.o.
				
		 		 	By:	 	 /s/ Yigal Pinto

		 		 		 	Yigal Pinto, its incorporator
			
		 		 	M. DAEMEN HOLDING B.V. i.o.
				
		 		 	By:	 	 /s/ Mat Daemen

		 		 		 	Mat Daemen, its incorporator
			
		 		 	TILMAN HACKENG HOLDING B.V. i.o.
				
		 		 	By:	 	 /s/ Tilman Hackeng

		 		 		 	Tilman Hackeng, its incorporator
			
		 		 	Marcel Kannekens
				
		 		 	By:	 	 /s/ Marcel Kannekens

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 5 

 Licensing Addendum No. 2 
 This Licensing Addendum No. 2 is entered into under and pursuant to the terms of the Product License and Collaboration Agreement dated
as of May 4, 2007 by and between BG Medicine, Inc., a Delaware corporation, ACS Biomarker B.V. i.o.,”), a corporation organized under the laws of The Netherlands to be established by the University of Maastricht (the
“University”), BioMedbooster B.V., a corporation organized under the laws of The Netherlands (“BioMedbooster”), ACS Holding B.V., a corporation organized under the laws of The Netherlands, to be established by Y. Pinto Holding
B.V. i.o. to be established by Yigal Pinto, M. Daemen Holding B.V. i.o. to be established by Mat Daemen, Tilman Hackeng Holding B.V. i.o. to be established by Tilman Hackeng, and Marcel Kannekens and the other parties thereto (the “Product
License Agreement”). In the event of any conflict between the Product License Agreement and the express terms of this Licensing Addendum, the terms of this Licensing Addendum shall prevail. Capitalized terms used but not defined in this
Licensing Addendum shall have the meanings assigned to them in the Product License Agreement. 
  

	1.	Subject IP. The following Intellectual Property Rights shall constitute Subject IP and therefore be licensed to BGM on the tenns set forth in the Product License
Agreement and in this Licensing Addendum: 

  

	 	a.	all rights of any nature in and to patent application no. EP 06009314.3 with a priority date of May 5, 2006, entitled “peptides for use in diagnosing the
presence of ruptured atherosclerotic lesions in an individual” and all related patents and patent applications (including, but not limited to, international application PCT/EP 2006.949 EP/PD (pub. no.) and any and all other foreign
applications, divisional applications, continuations, continuations in part, revisions, re-examinations and reissues anywhere in the world) that in full or in part can claim priority of said patent application (“ACSB Pre-Existing
IP”). To the extent ACSB does not possess the right to grant the License described in this Licensing Addendum as of the date hereof, such License shall become effective, and shall be deemed granted by ACSB, immediately upon ACSB’s
acquisition of such right. 

  

	 	b.	all rights of ACSB in any Intellectual Property developed by either Party under the Implementation Plan (as defined below), including without limitation (i) all
clinical, drug discovery, research, investigatory, or other methods, uses or applications and (ii) all Intellectual Property Rights throughout the world in any of the foregoing, including without limitation patents, the right to apply for
patents and trade secret or equivalent rights (“Jointly Developed IP”). 

 For the avoidance of
doubt, all rights of BGM in any Jointly Developed IP shall remain the sole and exclusive property of BGM, and ACSB shall not have any license or other rights thereto. 
  

	2.	 Exclusivity. The License granted under this Licensing Addendum shall be exclusive, even as to ACSB; provided, however, that in the event
BGM breaches any material term of the Implementation Plan, which breach is not cured within 30 days following written

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	 
notice thereof by ACSB to BGM, such License shall become non-exclusive and provided further, that ACSB, BioMedbooster, the University and their respective Affiliates shall have the limited
license to the ACSB Pre-Existing IP and Jointly Developed IP set forth in Section 2.01(a) of the Product License Agreement. 

  

	3.	Field of Use. The License granted under this Licensing Addendum shall permit BGM to use and exploit the ACSB Pre-Existing IP and Jointly Developed IP for any
purpose whatsoever. 

  

	4.	Term. The License granted under this Licensing Addendum shall be perpetual. 

  

	5.	Sublicensing. The License granted under this Licensing Addendum shall include the right to grant sublicenses to any of the rights of BGM.

  

	6.	Territory. The License granted under this Licensing Addendum shall be valid worldwide. 

  

	7.	Field of Interest. The Field of Interest shall include the field of atherothrombotic vascular disease, including non-ischemia angina. 

 

	8.	Activities, Rights and Obligations. The Parties shall undertake the activities, and have the rights and obligations, as follows: 

  

	 	a.	BGM and ACSB shall collaborate in good faith to develop a roadmap and implementation plan for development and commercialization of the ACSB Pre-Existing IP (the
“Implementation Plan”), and further agree that: 

  

	 	i.	BGM shall use commercially reasonable efforts to realize commencement of commercial distribution of Subject Products based on ACSB Pre-Existing IP to the extent
provided in the Implementation Plan, and shall inform ACSB at least once every calendar quarter about progress under the Implementation Plan. 

  

	 	ii.	ACSB shall provide such assistance in regard to the ACSB Pre-Existing IP and the activities described in the Implementation Plan as BGM shall reasonably request;
provided, however, that ACSB shall not be obligated to provide more than 100 man hours of such assistance in any twelve-month period unless BGM shall agree to compensate ACSB therefor at a reasonable commercial rate to be negotiated in good
faith by the Parties. 

  

	 	iii.	BGM shall reimburse ACSB for any out of pocket expenses reasonably incurred by ACSB in connection with the provision of such assistance. 

  

	 	b.	The Parties shall establish a scientific advisory board to provide input and guidance with respect to activities under the implementation Plan.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 2 

	9.	Royalties. The following royalties shall be payable by BGM to ACSB, in each case on the terms set forth in the Product License Agreement:

  

	 	a.	a royalty equal to [***]% of Net Sales from Subject Products in the Field of Interest described in paragraph 7 of this Licensing Addendum that are developed solely
using ACSB Pre-Existing IP. 

  

	 	b.	a royalty equal to [***]% of Sublicensing Income from Subject Products in the Field of Interest described in paragraph 7 of this Licensing Addendum that are developed
solely using ACSB Pre-Existing IP. 

  

	10.	Milestone Payments. BGM will make the following milestone payments to ACSB: 

  

	 	a.	$[***] payable within [***] days of the last to occur of (i) the formation of ACSB, (ii) the transfer or exclusive license of rights to ACSB by the University
and BioMedbooster described in paragraph 13.a. below and (iii) the termination of all other rights of Third Parties in and to the ACSB Pre-Existing IP. BGM’s obligation to make such payment shall be conditioned upon the delivery to BGM of
(A) documentation of such formation, transfer or licensing and termination in form and substance reasonably satisfactory to BGM and (B) a document in form and substance reasonably satisfactory to BGM and signed by ACSB ratifying the
Product License Agreement, this Licensing Addendum and any other Licensing Addenda then existing and acknowledging its obligations and status as a party hereunder and thereunder. 

  

	11.	Royalty Prepayment. BGM will make the royalty prepayment to ACSB described below. Such prepayment shall be credited against any royalties otherwise payable under
this Licensing Addendum or any other Licensing Addendum, but ACSB shall not be required to refund such prepayment. In the event that BGM pays royalties to ACSB under this or under any other Licensing Addendum, the amount of prepayment shall be
reduced by the amount of royalties so paid. 

  

	 	a.	$250,000 upon the occurrence of the first of the following events: 

  

	 	i.	Regulatory Approval for the US of a Subject Product within the Field of Interest described in paragraph 7 of this Licensing Addendum that has been developed using any
Jointly Developed IP or ACSB Pre-Existing IP; or 

  

	 	ii.	The issuance of a US or EU patent covering a Subject Product within the Field of Interest described in paragraph 7 of this Licensing Addendum that has been developed
using any Jointly Developed IP or ACSB Pre-Existing IP. 

  

	12.	Additional Representations and Warranties. The Parties make the following representations and warranties in addition to those set forth in the Product License
Agreement: 

  

	 	a.	 ACSB represents and warrants to BGM that, upon the transfer or exclusive license to ACSB of all rights of the University and BioMedbooster in and to
the ACSB Pre-Existing IP and the termination of any rights of [***] or its Affiliates

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 3 

	 	 
in and to the ACSB Pre-Existing IP, it will be the exclusive owner or exclusive licensee of all right, title and interest in the ACSB Pre-Existing IP, with full right, power and authority to
grant the License granted to BGM under this Licensing Addendum. 

  

	13.	Additional Terms. The following additional terms shall apply: 

  

	 	a.	The rights and obligations of BGM and ACSB under this Licensing Addendum are subject to the condition precedent that ACSB acquire all of the ACSB Pre-Existing IP. BGM
acknowledges that (i) some or all of the ACSB Pre-Existing IP is currently owned by one or more Third Parties and (ii) ACSB does not warrant in any way that this condition precedent will be fulfilled. 

  

	 	b.	In the event the condition precedent set forth in paragraph 13 a. above is not fulfilled within two years after the date of this Licensing Addendum, this Licensing
Addendum shall automatically terminate and the Parties will not have any obligations hereunder whatsoever. In the event ACSB acquires the ACSB Pre-Existing IP after such a termination, this Licensing Addendum shall impose no restriction on the
ability of ACSB to enter into any transaction with any third party related to the ACSB Pre-Existing IP. 

  

	 	c.	BGM shall reimburse patent prosecution costs previously incurred by ACSB in connection with the ACSB Pre-Existing IP upon presentation to BGM of appropriate
documentation, up to a maximum of $[***]. 

  

	 	d.	Each Party shall give the other Party prompt notice of the development of any Jointly Developed IP. 

 REMAINDER OF PAGE INTENTIONALLY LEFT BLANK 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 4 

 IN WITNESS WHEREOF, the Parties have executed this Licensing Addendum
No. 2 effective as of this 4th day of May, 2007.

  

							
	BG MEDICINE, INC.	 	 ACS BIOMARKER B.V., i.o.

			
		 		 	By its incorporators as listed below:
			
	By:	 	 /s/ Pieter Muntendam
	 	(i) THE UNIVERSITY OF MAASTRICHT
		 	Its President and CEO	 		 	
				
		 		 	 By:
	 	 /s/ Jo Ritzen

		 		 		 	Its President
			
		 		 	(ii) BIOMEDBOOSTER B.V.
				
		 		 	By:	 	 /s/ Tom Melvis

		 		 		 	Its Attorney
			
		 		 	(iii) ACS HOLDING B.V. i.o.
			
		 		 	By its incorporators as listed below:
			
		 		 	Y. PINTO HOLDING B.V. i.o.
				
		 		 	By:	 	 /s/ Yigal Pinto

		 		 		 	Yigal Pinto, its incorporator
			
		 		 	M. DAEMEN HOLDING B.V. i.o.
				
		 		 	By:	 	 /s/ Mat Daemen

		 		 		 	Mat Daemen, its incorporator
			
		 		 	TILMAN HACKENG HOLDING B.V. i.o.
				
		 		 	By:	 	 /s/ Tilman Hackeng

		 		 		 	Tilman Hackeng, its incorporator
			
		 		 	Marcel Kannekens
				
		 		 	By:	 	 /s/ Marcel Kannekens

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission
pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00168-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00168-of-00352.parquet"}]]